Ovarian Aging: Mechanisms, Age-Related Disorders, and Therapeutic Interventions

Abstract

Ovarian aging is a fundamental process in female reproductive biology with broad implications for overall health and aging. As global populations age, understanding its mechanisms and systemic effects has gained urgent clinical relevance. The ovary, beyond its reproductive role, is increasingly recognized as a regulator of systemic aging due to the widespread presence of estrogen receptors. Declining ovarian function accelerates not only reproductive senescence but also contributes to age-related disorders including osteoporosis, neurodegenerative diseases, and cardiovascular conditions. However, research on ovarian aging remains fragmented, lacking integrative analysis. This review synthesizes recent advances in the cellular and molecular mechanisms underpinning ovarian aging, such as genomic instability, metabolic and oxidative stress, and microenvironmental alterations. It further discusses how ovarian decline influences systemic aging pathways and disease susceptibility and evaluates emerging therapeutic strategies such as antioxidant interventions, stem cell therapy, and ovarian tissue transplantation. By providing a comprehensive overview of ovarian aging from mechanisms to interventions, this review aims to bridge existing knowledge gaps and inspire future research toward improving women's healthspan and quality of life.

Keywords

age-related diseases / mechanism / ovarian aging / therapeutic interventions

References

[1] Z. Zhu, W. Xu, and L. Liu, “Ovarian Aging: Mechanisms and Intervention Strategies,” Medical Review (2021) 2, no. 6 (2022): 590–610.

[2] K. L. Marlatt, D. R. Pitynski-Miller, K. M. Gavin, et al., “Body Composition and Cardiometabolic Health Across the Menopause Transition,” Obesity (Silver Spring) 30, no. 1 (2022): 14–27.

[3] W. A. Rocca, L. Gazzuola Rocca, C. Y. Smith, et al., “Loss of Ovarian Hormones and Accelerated Somatic and Mental Aging,” Physiology (Bethesda, Md) 33, no. 6 (2018): 374–383.

[4] S. R. Davis, J. Pinkerton, N. Santoro, and T. Simoncini, “Menopause-Biology, Consequences, Supportive Care, and Therapeutic Options,” Cell 186, no. 19 (2023): 4038–4058.

[5] A. LePillouer-Prost, D. Kerob, M. Nielsen, C. Taieb, and L. Maitrot Mantelet, “Skin and Menopause: Women's Point of View,” Journal of the European Academy of Dermatology and Venereology 34, no. 6 (2020): e267–e269.

[6] A. G. Kattah, C. Y. Smith, L. Gazzuola Rocca, B. R. Grossardt, V. D. Garovic, and W. A. Rocca, “CKD in Patients With Bilateral Oophorectomy,” Clinical Journal of the American Society of Nephrology 13, no. 11 (2018): 1649–1658.

[7] G. H. Goossens, J. W. E. Jocken, and E. E. Blaak, “Sexual Dimorphism in Cardiometabolic Health: The Role of Adipose Tissue, Muscle and Liver,” Nature Reviews Endocrinology 17, no. 1 (2021): 47–66.

[8] C. Liang, H. F. Chung, A. Dobson, S. Sandin, E. Weiderpass, and G. D. Mishra, “Female Reproductive Histories and the Risk of Chronic Obstructive Pulmonary Disease,” Thorax 79, no. 6 (2024): 508–514.

[9] L. Dong, D. B. L. Teh, B. K. Kennedy, and Z. Huang, “Unraveling Female Reproductive Senescence to Enhance Healthy Longevity,” Cell Research 33, no. 1 (2023): 11–29.

[10] X. Liu, Y. Zhao, Y. Feng, S. Wang, A. Luo, and J. Zhang, “Ovarian Aging: The Silent Catalyst of Age-Related Disorders in Female Body,” Aging and Disease (2025).

[11] W. Tang, K. Wang, Y. Feng, et al., “Exploration of the Mechanism and Therapy of Ovarian Aging by Targeting Cellular Senescence,” Life Medicine 4, no. 1 (2025): lnaf004.

[12] J. V. V. Isola, J. D. Hense, C. A. P. Osório, et al., “Reproductive Ageing: Inflammation, Immune Cells, and Cellular Senescence in the Aging Ovary,” Reproduction (Cambridge, England) 168, no. 2 (2024): e230499.

[13] A. C. de Kat, W. M. Verschuren, M. J. Eijkemans, F. J. Broekmans, and Y. T. van der Schouw, “Anti-Müllerian Hormone Trajectories Are Associated with Cardiovascular Disease in Women: Results from the Doetinchem Cohort Study,” Circulation 135, no. 6 (2017): 556–565.

[14] A. Fallahzadeh, F. Ramezeni Tehrani, M. Rezaee, F. Mahboobifard, and M. Amiri, “Anti-Mullerian Hormone and Cardiometabolic Status: A Systematic Review,” Biomarkers 28, no. 6 (2023): 486–501.

[15] M. Z. Md Muslim, A. Mohammed Jelani, N. Shafii, N. M. Yaacob, N. A. A. Che Soh, and H. A. Ibrahim, “Correlation Between anti-mullerian Hormone With Insulin Resistance in Polycystic Ovarian Syndrome: A Systematic Review and Meta-analysis,” Journal of Ovarian Research 17, no. 1 (2024): 106.

[16] S. U. Park, L. Walsh, and K. M. Berkowitz, “Mechanisms of Ovarian Aging,” Reproduction (Cambridge, England) 162, no. 2 (2021): R19–R33.

[17] S. Desai and A. Rajkovic, “Genetics of Reproductive Aging From Gonadal Dysgenesis Through Menopause,” Seminars in Reproductive Medicine 35, no. 2 (2017): 147–159.

[18] L. Secomandi, M. Borghesan, M. Velarde, and M. Demaria, “The Role of Cellular Senescence in Female Reproductive Aging and the Potential for Senotherapeutic Interventions,” Human Reproduction Update 28, no. 2 (2022): 172–189.

[19] S. Huber and M. Fieder, “Evidence for a Maximum “Shelf-life” of Oocytes in Mammals Suggests That human Menopause May be an Implication of Meiotic Arrest,” Scientific Reports 8, no. 1 (2018): 14099.

[20] P. May-Panloup, L. Boucret, J. M. Chao de la Barca, et al., “Ovarian Ageing: The Role of Mitochondria in Oocytes and Follicles,” Human Reproduction Update 22, no. 6 (2016): 725–743.

[21] H. Kobayashi and S. Imanaka, “Mitochondrial DNA Damage and Its Repair Mechanisms in Aging Oocytes,” International Journal of Molecular Sciences 25, no. 23 (2024): 13144.

[22] Working Group on the update of the ESHRE/ALPHA Istanbul Consensus, G. Coticchio, A. Ahlström, et al., Working Group on the update of the ESHRE/ALPHA Istanbul Consensus, “The Istanbul Consensus Update: A Revised ESHRE/ALPHA Consensus on Oocyte and Embryo Static and Dynamic Morphological Assessment,” Human Reproduction 40, no. 6 (2025): 989–1035.

[23] U. Al-Zubaidi, J. Liu, O. Cinar, R. L. Robker, D. Adhikari, and J. Carroll, “The Spatio-temporal Dynamics of Mitochondrial Membrane Potential During Oocyte Maturation,” Molecular Human Reproduction 25, no. 11 (2019): 695–705.

[24] X. Sun, D. Wang, W. Li, Q. Gao, J. Tao, and H. Liu, “Comprehensive Analysis of Nonsurrounded Nucleolus and Surrounded Nucleolus Oocytes on Chromatin Accessibility Using ATAC-seq,” Molecular Reproduction and Development 90, no. 2 (2023): 87–97.

[25] H. Balakier, A. Sojecki, G. Motamedi, S. Bashar, R. Mandel, and C. Librach, “Is the Zona Pellucida Thickness of human Embryos Influenced by Women's Age and Hormonal Levels?,” Fertility and Sterility 98, no. 1 (2012): 77–83.

[26] M. Kawakami, T. Okimura, K. Uchiyama, A. Yabuuchi, T. Kobayashi, and K. Kato, “The Effect of Zona Pellucida Thickness Variation on Fertilization and Subsequent Embryonic Development: A Large Single Center Cohort Study,” Fertility and Sterility 112, no. 3 (2019): e128–e129.

[27] T. Ebner, M. Moser, M. Sommergruber, C. Yaman, U. Pfleger, and G. Tews, “First Polar Body Morphology and Blastocyst Formation Rate in ICSI Patients,” Human Reproduction 17, no. 9 (2002): 2415–2418.

[28] E. G. Qassem, K. M. Falah, I. Aghaways, and T. A. Salih, “A Correlative Study of Oocytes Morphology With Fertilization, Cleavage, Embryo Quality and Implantation Rates After Intra Cytoplasmic Sperm Injection,” Acta Medica International 2, no. 1 (2015): 7–13.

[29] P. Fancsovits, Z. G. Tóthné, Á. Murber, J. Rigo, and J. Urbancsek, “Importance of Cytoplasmic Granularity of human Oocytes in in Vitro Fertilization Treatments,” Acta Biologica Hungarica 63, no. 2 (2012): 189–201.

[30] P. Merviel, R. Cabry, K. Chardon, et al., “Impact of Oocytes With CLCG on ICSI Outcomes and Their Potential Relation to Pesticide Exposure,” Journal of Ovarian Research 10, no. 1 (2017): 42.

[31] C. Chen, S. Han, W. Liu, Y. Wang, and G. Huang, “Effect of Vitrification on Mitochondrial Membrane Potential in human Metaphase II Oocytes,” Journal of Assisted Reproduction and Genetics 29, no. 10 (2012): 1045–1050.

[32] J. Van Blerkom, “Mitochondrial Function in the human Oocyte and Embryo and Their Role in Developmental Competence,” Mitochondrion 11, no. 5 (2011): 797–813.

[33] A. Inoue, R. Nakajima, M. Nagata, and F. Aoki, “Contribution of the Oocyte Nucleus and Cytoplasm to the Determination of Meiotic and Developmental Competence in Mice,” Human Reproduction 23, no. 6 (2008): 1377–1384.

[34] C. Liu, W. Zuo, G. Yan, et al., “Granulosa Cell Mevalonate Pathway Abnormalities Contribute to Oocyte Meiotic Defects and Aneuploidy,” Nature Aging 3, no. 6 (2023): 670–687.

[35] Y. Wang, Y. Qi, W. Xie, Y. Zhang, Y. Yu, and Y. Fan, “P-682 Malic Enzyme 1 in Granulosa Cells Promotes Ovarian Aging Through Inhibiting the AMPK-FoXO1-IDH2 Signaling Pathway,” Human Reproduction 39, no. Supplement_1 (2024): deae108. 1012.

[36] H. Wang, Z. Huang, X. Shen, et al., “Rejuvenation of Aged Oocyte Through Exposure to Young Follicular Microenvironment,” Nature Aging 4, no. 9 (2024): 1194–1210.

[37] C. Huang, T. Guo, and Y. Qin, “Meiotic Recombination Defects and Premature Ovarian Insufficiency,” Frontiers in Cell and Developmental Biology 9 (2021): 652407.

[38] M. A. Handel and J. C. Schimenti, “Genetics of Mammalian Meiosis: Regulation, Dynamics and Impact on Fertility,” Nature Reviews Genetics 11, no. 2 (2010): 124–136.

[39] S. Wang, Y. Liu, Y. Shang, et al., “Crossover Interference, Crossover Maturation, and Human Aneuploidy,” BioEssays 41, no. 10 (2019): e1800221.

[40] M. Mikwar, A. J. MacFarlane, and F. Marchetti, “Mechanisms of Oocyte Aneuploidy Associated With Advanced Maternal Age,” Mutation Research Reviews in Mutation Research 785 (2020): 108320.

[41] J. Greaney, Z. Wei, and H. Homer, “Regulation of Chromosome Segregation in Oocytes and the Cellular Basis for Female Meiotic Errors,” Human Reproduction Update 24 (2018): 135–161.

[42] S. Wang, T. Hassold, P. Hunt, et al., “Inefficient Crossover Maturation Underlies Elevated Aneuploidy in Human Female Meiosis,” Cell 168, no. 6 (2017): 977–989.e17.

[43] A. J. Wood, A. F. Severson, and B. J. Meyer, “Condensin and Cohesin Complexity: The Expanding Repertoire of Functions,” Nature Reviews Genetics 11, no. 6 (2010): 391–404.

[44] S. Burkhardt, M. Borsos, A. Szydlowska, et al., “Chromosome Cohesion Established by Rec8-Cohesin in Fetal Oocytes Is Maintained Without Detectable Turnover in Oocytes Arrested for Months in Mice,” Current Biology 26, no. 5 (2016): 678–685.

[45] Y. Miao, C. Zhou, Z. Cui, et al., “Smc1β is Required for Activation of SAC During Mouse Oocyte Meiosis,” Cell Cycle 16, no. 6 (2017): 536–544.

[46] E. J. Tucker, K. M. Bell, G. Robevska, et al., “Meiotic Genes in Premature Ovarian Insufficiency: Variants in HROB and REC8 as Likely Genetic Causes,” European Journal of Human Genetics 30, no. 2 (2022): 219–228.

[47] M. Tsutsumi, R. Fujiwara, H. Nishizawa, et al., “Age-related Decrease of Meiotic Cohesins in human Oocytes,” PLoS ONE 9, no. 5 (2014): e96710.

[48] R. Garcia-Cruz, M. A. Brieño, I. Roig, et al., “Dynamics of Cohesin Proteins REC8, STAG3, SMC1 Beta and SMC3 Are Consistent With a Role in Sister Chromatid Cohesion During Meiosis in human Oocytes,” Human Reproduction 25, no. 9 (2010): 2316–2327.

[49] Y. Watanabe, “Geometry and Force Behind Kinetochore Orientation: Lessons From Meiosis,” Nature Reviews Molecular Cell Biology 13, no. 6 (2012): 370–382.

[50] B. P. Mihalas, G. H. Pieper, M. Aboelenain, et al., “Age-dependent Loss of Cohesion Protection in human Oocytes,” Current Biology 34, no. 1 (2024): 117–131.e5.

[51] I. Nabti, R. Grimes, H. Sarna, P. Marangos, and J. Carroll, “Maternal Age-dependent APC/C-mediated Decrease in Securin Causes Premature Sister Chromatid Separation in Meiosis II,” Nature Communications 8 (2017): 15346.

[52] J. Lagirand-Cantaloube, C. Ciabrini, S. Charrasse, et al., “Loss of Centromere Cohesion in Aneuploid Human Oocytes Correlates With Decreased Kinetochore Localization of the Sac Proteins Bub1 and Bubr1,” Scientific Reports 7 (2017): 44001.

[53] J. Maciejowski and T. de Lange, “Telomeres in Cancer: Tumour Suppression and Genome Instability,” Nature Reviews Molecular Cell Biology 18, no. 3 (2017): 175–186.

[54] D. Chakravarti, K. A. LaBella, and R. A. DePinho, “Telomeres: History, Health, and Hallmarks of Aging,” Cell 184, no. 2 (2021): 306–322.

[55] E. G. Kosebent, F. Uysal, and S. Ozturk, “The Altered Expression of Telomerase Components and Telomere-linked Proteins May Associate With Ovarian Aging in Mouse,” Experimental Gerontology 138 (2020): 110975.

[56] K. E. Gray, M. A. Schiff, A. L. Fitzpatrick, M. Kimura, A. Aviv, and J. R. Starr, “Leukocyte Telomere Length and Age at Menopause,” Epidemiology (Cambridge, Mass) 25, no. 1 (2014): 139–146.

[57] N. R. Treff, J. Su, D. Taylor, and R. T. Scott, “Telomere DNA Deficiency Is Associated With Development of human Embryonic Aneuploidy,” PLOS Genetics 7, no. 6 (2011): e1002161.

[58] D. L. Keefe, S. Franco, L. Liu, et al., “Telomere Length Predicts Embryo Fragmentation After in Vitro Fertilization in Women–Toward a Telomere Theory of Reproductive Aging in Women,” American Journal of Obstetrics and Gynecology 192, no. 4 (2005): 1256–1260. discussion 60–1.

[59] R. J. O'Sullivan and J. Karlseder, “Telomeres: Protecting Chromosomes Against Genome Instability,” Nature Reviews Molecular Cell Biology 11, no. 3 (2010): 171–181.

[60] G. De Boeck, R. G. Forsyth, M. Praet, and P. C. Hogendoorn, “Telomere-associated Proteins: Cross-talk Between Telomere Maintenance and Telomere-lengthening Mechanisms,” Journal of Pathology 217, no. 3 (2009): 327–344.

[61] F. Uysal, E. G. Kosebent, H. S. Toru, and S. Ozturk, “Decreased Expression of TERT and Telomeric Proteins as human Ovaries Age May Cause Telomere Shortening,” Journal of Assisted Reproduction and Genetics 38, no. 2 (2021): 429–441.

[62] K. H. Kalmbach, D. M. Antunes, F. Kohlrausch, and D. L. Keefe, “Telomeres and Female Reproductive Aging,” Seminars in Reproductive Medicine 33, no. 6 (2015): 389–395.

[63] X. Xu, X. Chen, X. Zhang, et al., “Impaired Telomere Length and Telomerase Activity in Peripheral Blood Leukocytes and Granulosa Cells in Patients With Biochemical Primary Ovarian Insufficiency,” Human Reproduction 32, no. 1 (2017): 201–207.

[64] S. Butts, H. Riethman, S. Ratcliffe, A. Shaunik, C. Coutifaris, and K. Barnhart, “Correlation of Telomere Length and Telomerase Activity With Occult Ovarian Insufficiency,” Journal of Clinical Endocrinology and Metabolism 94, no. 12 (2009): 4835–4843.

[65] J. P. Liu and H. Li, “Telomerase in the Ovary,” Reproduction (Cambridge, England) 140, no. 2 (2010): 215–222.

[66] S. Bayne, H. Li, M. E. Jones, et al., “Estrogen Deficiency Reversibly Induces Telomere Shortening in Mouse Granulosa Cells and Ovarian Aging in Vivo,” Protein Cell 2, no. 4 (2011): 333–346.

[67] K. S. Ruth, F. R. Day, J. Hussain, et al., “Genetic Insights Into Biological Mechanisms Governing human Ovarian Ageing,” Nature 596, no. 7872 (2021): 393–397.

[68] D. Zhang, X. Zhang, M. Zeng, et al., “Increased DNA Damage and Repair Deficiency in Granulosa Cells Are Associated With Ovarian Aging in rhesus monkey,” Journal of Assisted Reproduction and Genetics 32, no. 7 (2015): 1069–1078.

[69] J. Dias Nunes, I. Demeestere, and M. Devos, “BRCA Mutations and Fertility Preservation,” International Journal of Molecular Sciences 25, no. 1 (2023): 204.

[70] V. Turan and K. Oktay, “BRCA-related ATM-mediated DNA Double-strand Break Repair and Ovarian Aging,” Human Reproduction Update 26, no. 1 (2020): 43–57.

[71] R. Suzuki, X. Tan, K. J. Szymanska, et al., “The Role of Declining Ataxia-telangiectasia-mutated (ATM) Function in Oocyte Aging,” Cell Death Discovery 10, no. 1 (2024): 302.

[72] L. D. Ward, M. M. Parker, A. M. Deaton, et al., “Rare Coding Variants in DNA Damage Repair Genes Associated With Timing of Natural Menopause,” Human Genetics and Genomics Advances 3, no. 2 (2022): 100079.

[73] M. C. Lanz, D. Dibitetto, and M. B. Smolka, “DNA Damage Kinase Signaling: Checkpoint and Repair at 30 Years,” The EMBO Journal 38, no. 18 (2019): e101801.

[74] M. Mills, C. Emori, P. Kumar, Z. Boucher, J. George, and E. Bolcun-Filas, “Single-cell and Bulk Transcriptional Profiling of Mouse Ovaries Reveals Novel Genes and Pathways Associated With DNA Damage Response in Oocytes,” Developmental Biology 517 (2025): 55–72.

[75] H. Bao, J. Cao, M. Chen, et al., “Biomarkers of Aging,” Science China Life Sciences 66, no. 5 (2023): 893–1066.

[76] M. A. J. Smits, B. V. Schomakers, M. van Weeghel, et al., “Human Ovarian Aging Is Characterized by Oxidative Damage and Mitochondrial Dysfunction,” Human Reproduction 38, no. 11 (2023): 2208–2220.

[77] L. Khosla, S. Gong, J. P. Weiss, and L. A. Birder, “Oxidative Stress Biomarkers in Age-Related Lower Urinary Tract Disorders: A Systematic Review,” International Neurourology Journal 26, no. 1 (2022): 3–19.

[78] S. Qin, X. Chi, Z. Zhu, et al., “Oocytes Maintain Low ROS Levels to Support the Dormancy of Primordial Follicles,” Aging Cell 24, no. 1 (2024): e14338.

[79] L. C. D. Pomatto and K. J. A. Davies, “Adaptive Homeostasis and the Free Radical Theory of Ageing,” Free Radical Biology and Medicine 124 (2018): 420–430.

[80] J. Ávila, R. González-Fernández, D. Rotoli, J. Hernández, and A. Palumbo, “Oxidative Stress in Granulosa-Lutein Cells from in Vitro Fertilization Patients,” Reproductive Sciences 23, no. 12 (2016): 1656–1661.

[81] Y. Chen, J. Zhang, Y. Tian, et al., “Iron Accumulation in Ovarian Microenvironment Damages the Local Redox Balance and Oocyte Quality in Aging Mice,” Redox Biology 73 (2024): 103195.

[82] M. H. Stensen, T. Tanbo, R. Storeng, and P. Fedorcsak, “Advanced Glycation End Products and Their Receptor Contribute to Ovarian Ageing,” Human Reproduction 29, no. 1 (2014): 125–134.

[83] M. Jinno, M. Takeuchi, A. Watanabe, et al., “Advanced Glycation End-products Accumulation Compromises Embryonic Development and Achievement of Pregnancy by Assisted Reproductive Technology,” Human Reproduction 26, no. 3 (2011): 604–610.

[84] N. Takahashi, M. Harada, J. M. K. Azhary, et al., “Accumulation of Advanced Glycation End Products in Follicles Is Associated With Poor Oocyte Developmental Competence,” Molecular Human Reproduction 25, no. 11 (2019): 684–694.

[85] M. Pertynska-Marczewska and E. Diamanti-Kandarakis, “Aging Ovary and the Role for Advanced Glycation End Products,” Menopause 24, no. 3 (2017): 345–351.

[86] A. Goldin, J. A. Beckman, A. M. Schmidt, and M. A. Creager, “Advanced Glycation End Products: Sparking the Development of Diabetic Vascular Injury,” Circulation 114, no. 6 (2006): 597–605.

[87] P. M. Motta, S. A. Nottola, S. Makabe, and R. Heyn, “Mitochondrial Morphology in human Fetal and Adult Female Germ Cells,” Human Reproduction 15 Suppl 2 (2000): 129–147.

[88] T. Wang, M. Zhang, Z. Jiang, and E. Seli, “Mitochondrial Dysfunction and Ovarian Aging,” American Journal of Reproductive Immunology 77, no. 5 (2017): e12651.

[89] K. L. DeBalsi, K. E. Hoff, and W. C. Copeland, “Role of the Mitochondrial DNA Replication Machinery in Mitochondrial DNA Mutagenesis, Aging and Age-related Diseases,” Ageing Research Reviews 33 (2017): 89–104.

[90] S. Wang, Y. Zheng, J. Li, et al., “Single-Cell Transcriptomic Atlas of Primate Ovarian Aging,” Cell 180, no. 3 (2020): 585–600.e19.

[91] J. M. Stringer, L. R. Alesi, A. L. Winship, and K. J. Hutt, “Beyond Apoptosis: Evidence of Other Regulated Cell Death Pathways in the Ovary throughout Development and Life,” Human Reproduction Update 29, no. 4 (2023): 434–456.

[92] X. Wang, L. Wang, and W. Xiang, “Mechanisms of Ovarian Aging in Women: A Review,” Journal of Ovarian Research 16, no. 1 (2023): 67.

[93] F. Matsuda, N. Inoue, N. Manabe, and S. Ohkura, “Follicular Growth and Atresia in Mammalian Ovaries: Regulation by Survival and Death of Granulosa Cells,” The Journal of Reproduction and Development 58, no. 1 (2012): 44–50.

[94] J. A. Flaws, A. N. Hirshfield, J. A. Hewitt, J. K. Babus, and P. A. Furth, “Effect of Bcl-2 on the Primordial Follicle Endowment in the Mouse Ovary,” Biology of Reproduction 64, no. 4 (2001): 1153–1159.

[95] H. Xi, X. Chen, X. Wang, F. Jiang, and D. Niu, “Role of Programmed Cell Death in Mammalian Ovarian Follicular Atresia,” Journal of Steroid Biochemistry and Molecular Biology 247 (2024): 106667.

[96] X. Duan, X. X. Dai, T. Wang, H. L. Liu, and S. C. Sun, “Melamine Negatively Affects Oocyte Architecture, Oocyte Development and Fertility in Mice,” Human Reproduction 30, no. 7 (2015): 1643–1652.

[97] Q. Li, M. Cai, J. Wang, et al., “Decreased Ovarian Function and Autophagy Gene Methylation in Aging Rats,” Journal of Ovarian Research 13, no. 1 (2020): 12.

[98] Y. Yao, B. Wang, K. Yu, et al., “Nur77 improves Ovarian Function in Reproductive Aging Mice by Activating Mitophagy and Inhibiting Apoptosis,” Reproductive Biology and Endocrinology [Electronic Resource]: RB&E 22, no. 1 (2024): 86.

[99] F. E. Duncan, S. Jasti, A. Paulson, J. M. Kelsh, B. Fegley, and J. L. Gerton, “Age-associated Dysregulation of Protein Metabolism in the Mammalian Oocyte,” Aging Cell 16, no. 6 (2017): 1381–1393.

[100] T. Lin, J. E. Lee, J. W. Kang, H. Y. Shin, J. B. Lee, and D. I. Jin, “Endoplasmic Reticulum (ER) Stress and Unfolded Protein Response (UPR) in Mammalian Oocyte Maturation and Preimplantation Embryo Development,” International Journal of Molecular Sciences 20, no. 2 (2019): 409.

[101] T. Wang, E. Babayev, Z. Jiang, et al., “Mitochondrial Unfolded Protein Response Gene Clpp Is Required to Maintain Ovarian Follicular Reserve During Aging, for Oocyte Competence, and Development of Pre-implantation Embryos,” Aging Cell 17, no. 4 (2018): e12784.

[102] P. M. Quirós, T. Langer, and C. López-Otín, “New Roles for Mitochondrial Proteases in Health, Ageing and Disease,” Nature Reviews Molecular Cell Biology 16, no. 6 (2015): 345–359.

[103] L. Gibellini, A. De Gaetano, M. Mandrioli, et al., “The Biology of Lonp1: More Than a Mitochondrial Protease,” International Review of Cell and Molecular Biology 354 (2020): 1–61.

[104] M. Pinti, L. Gibellini, Y. Liu, S. Xu, B. Lu, and A. Cossarizza, “Mitochondrial Lon Protease at the Crossroads of Oxidative Stress, Ageing and Cancer,” Cellular and Molecular Life Sciences 72, no. 24 (2015): 4807–4824.

[105] C. Liu, M. Xu, Y. Guan, et al., “Decreased LONP1 Expression Contributes to DNA Damage and Meiotic Defects in Oocytes,” Molecular Reproduction and Development 90, no. 6 (2023): 358–368.

[106] X. Sheng, C. Liu, G. Yan, et al., “The Mitochondrial Protease LONP1 Maintains Oocyte Development and Survival by Suppressing Nuclear Translocation of AIFM1 in Mammals,” EBioMedicine 75 (2022): 103790.

[107] Y. Liu, J. J. Jiang, S. Y. Du, et al., “Artemisinins Ameliorate Polycystic Ovarian Syndrome by Mediating LONP1-CYP11A1 Interaction,” Science 384 (2024): 6701.

[108] Y. Y. Zhou, Y. Q. Wu, C. J. Chong, et al., “Irpex Lacteus Polysaccharide Exhibits Therapeutic Potential for Ovarian Fibrosis in PCOS Rats via the TGF-β1/Smad Pathway,” Heliyon 9, no. 8 (2023): e18741.

[109] Y. Zhou, H. Lan, Z. Dong, et al., “Rhamnocitrin Attenuates Ovarian Fibrosis in Rats With Letrozole-Induced Experimental Polycystic Ovary Syndrome,” Oxidative Medicine and Cellular Longevity 2022 (2022): 5558599.

[110] Y. Zhang and D. Zhang, “FSH/FSHR/TGF-β1/SMADS Signaling Cascade Mediates Ovarian Fibrosis Resulting in Ovarian Aging,” Fertility and Sterility 120, no. 4 (2023): e33.

[111] L. Zhao, D. Wu, M. Sang, Y. Xu, Z. Liu, and Q. Wu, “Stachydrine Ameliorates Isoproterenol-induced Cardiac Hypertrophy and Fibrosis by Suppressing Inflammation and Oxidative Stress Through Inhibiting NF-κB and JAK/STAT Signaling Pathways in Rats,” International Immunopharmacology 48 (2017): 102–109.

[112] A. Reicherz, F. Eltit, K. Scotland, et al., “Indwelling Stents Cause Severe Inflammation and Fibrosis of the Ureter via Urothelial-mesenchymal Transition,” Scientific Reports 13, no. 1 (2023): 5492.

[113] S. M. Briley, S. Jasti, J. M. McCracken, et al., “Reproductive Age-associated Fibrosis in the Stroma of the Mammalian Ovary,” Reproduction (Cambridge, England) 152, no. 3 (2016): 245–260.

[114] F. Amargant, S. L. Manuel, Q. Tu, et al., “Ovarian Stiffness Increases With Age in the Mammalian Ovary and Depends on Collagen and Hyaluronan Matrices,” Aging Cell 19, no. 11 (2020): e13259.

[115] E. Ouni, C. Bouzin, M. M. Dolmans, et al., “Spatiotemporal Changes in Mechanical Matrisome Components of the human Ovary From Prepuberty to Menopause,” Human Reproduction 35, no. 6 (2020): 1391–1410.

[116] H. Wang and L. Yang, “Ovarian Mechanobiology: Understanding the Interplay between Mechanics and Follicular Development,” Cells 14, no. 5 (2025): 355.

[117] A. Nishigaki, H. Tsubokura, T. Tsuzuki-Nakao, and H. Okada, “Hypoxia: Role of SIRT1 and the Protective Effect of Resveratrol in Ovarian Function,” Reproductive Medicine and Biology 21, no. 1 (2022): e12428.

[118] M. Gu, Y. Wang, and Y. Yu, “Ovarian Fibrosis: Molecular Mechanisms and Potential Therapeutic Targets,” Journal of Ovarian Research 17, no. 1 (2024): 139.

[119] J. H. Machlin, S. J. Barishansky, J. Kelsh, et al., “Fibroinflammatory Signatures Increase With Age in the Human Ovary and Follicular Fluid,” International Journal of Molecular Sciences 22, no. 9 (2021): 4902.

[120] Y. Zeng, C. Wang, C. Yang, X. Shan, X. Q. Meng, and M. Zhang, “Unveiling the Role of Chronic Inflammation in Ovarian Aging: Insights Into Mechanisms and Clinical Implications,” Human Reproduction 39, no. 8 (2024): 1599–1607.

[121] L. L. Cui, G. Yang, J. Pan, and C. Zhang, “Tumor Necrosis Factor α Knockout Increases Fertility of Mice,” Theriogenology 75, no. 5 (2011): 867–876.

[122] S. Uri-Belapolsky, A. Shaish, E. Eliyahu, et al., “Interleukin-1 Deficiency Prolongs Ovarian Lifespan in Mice,” Proceedings of the National Academy of Sciences of the United States of America 111, no. 34 (2014): 12492–12497.

[123] M. Tang, M. Zhao, and Y. Shi, “New Insight Into the Role of Macrophages in Ovarian Function and Ovarian Aging,” Frontiers in Endocrinology (Lausanne) 14 (2023): 1282658.

[124] X. Lv, S. Cui, X. Zhang, and C. Ren, “Efficacy and Safety of Neoadjuvant Chemotherapy versus Primary Debulking Surgery in Patients With Ovarian Cancer: A Meta-analysis,” Journal of Gynecologic Oncology 31, no. 2 (2020): e12.

[125] T. Umehara, Y. E. Winstanley, E. Andreas, et al., “Female Reproductive Life Span Is Extended by Targeted Removal of Fibrotic Collagen From the Mouse Ovary,” Science Advances 8, no. 24 (2022): eabn4564.

[126] G. F. Vasse, M. Nizamoglu, I. H. Heijink, et al., “Macrophage-stroma Interactions in Fibrosis: Biochemical, Biophysical, and Cellular Perspectives,” Journal of Pathology 254, no. 4 (2021): 344–357.

[127] T. Lazarov, S. Juarez-Carreño, N. Cox, and F. Geissmann, “Physiology and Diseases of Tissue-resident Macrophages,” Nature 618, no. 7966 (2023): 698–707.

[128] Y. Lavin, A. Mortha, A. Rahman, and M. Merad, “Regulation of Macrophage Development and Function in Peripheral Tissues,” Nature Reviews Immunology 15, no. 12 (2015): 731–744.

[129] C. Lliberos, S. H. Liew, A. Mansell, and K. J. Hutt, “The Inflammasome Contributes to Depletion of the Ovarian Reserve during Aging in Mice,” Frontiers in Cell and Developmental Biology 8 (2020): 628473.

[130] G. Wang, R. Yang, and H. Zhang, “Ovarian Vascular Aging: A Hidden Driver of Mid-age Female Fertility Decline,” NPJ Aging 11, no. 1 (2025): 24.

[131] X. Xu, L. Mu, L. Li, et al., “Imaging and Tracing the Pattern of Adult Ovarian Angiogenesis Implies a Strategy Against Female Reproductive Aging,” Science Advances 8, no. 2 (2022): eabi8683.

[132] L. Mu, G. Wang, X. Yang, et al., “Physiological Premature Aging of Ovarian Blood Vessels Leads to Decline in Fertility in Middle-aged Mice,” Nature Communications 16, no. 1 (2025): 72.

[133] G. Grisotto, J. S. Farago, P. E. Taneri, et al., “Dietary Factors and Onset of Natural Menopause: A Systematic Review and Meta-analysis,” Maturitas 159 (2022): 15–32.

[134] M. E. Boutot, A. Purdue-Smithe, B. W. Whitcomb, et al., “Dietary Protein Intake and Early Menopause in the Nurses' Health Study II,” American Journal of Epidemiology 187, no. 2 (2018): 270–277.

[135] G. Grisotto, C. R. Langton, Y. Li, et al., “Association of Plant-based Diet and Early Onset of Natural Menopause,” Menopause 29, no. 7 (2022): 861–867.

[136] A. N. Shelling and N. Ahmed Nasef, “The Role of Lifestyle and Dietary Factors in the Development of Premature Ovarian Insufficiency,” Antioxidants (Basel) 12, no. 8 (2023): 1601.

[137] L. L. Wu, K. R. Dunning, X. Yang, et al., “High-fat Diet Causes Lipotoxicity Responses in Cumulus-oocyte Complexes and Decreased Fertilization Rates,” Endocrinology 151, no. 11 (2010): 5438–5445.

[138] R. L. Robker, L. K. Akison, B. D. Bennett, et al., “Obese Women Exhibit Differences in Ovarian Metabolites, Hormones, and Gene Expression Compared With Moderate-weight Women,” Journal of Clinical Endocrinology and Metabolism 94, no. 5 (2009): 1533–1540.

[139] S. L. Gudmundsdottir, W. D. Flanders, and L. B. Augestad, “Physical Activity and Age at Menopause: The Nord-Trøndelag Population-based Health Study,” Climacteric 16, no. 1 (2013): 78–87.

[140] O. Hakimi and L. C. Cameron, “Effect of Exercise on Ovulation: A Systematic Review,” Sports Medicine (Auckland, NZ) 47, no. 8 (2017): 1555–1567.

[141] G. G. Collins and B. V. Rossi, “The Impact of Lifestyle Modifications, Diet, and Vitamin Supplementation on Natural Fertility,” Fertility Research and Practice 1 (2015): 11.

[142] S. Firns, V. F. Cruzat, K. N. Keane, et al., “The Effect of Cigarette Smoking, Alcohol Consumption and Fruit and Vegetable Consumption on IVF Outcomes: A Review and Presentation of Original Data,” Reproductive Biology and Endocrinology [Electronic Resource]: RB&E 13 (2015): 134.

[143] M. B. Cavalcante, O. G. M. Sampaio, F. E. A. Câmara, et al., “Ovarian Aging in Humans: Potential Strategies for Extending Reproductive Lifespan,” Geroscience 45, no. 4 (2023): 2121–2133.

[144] N. Evangelinakis, E. V. Geladari, C. V. Geladari, et al., “The Influence of Environmental Factors on Premature Ovarian Insufficiency and Ovarian Aging,” Maturitas 179 (2024): 107871.

[145] L. Medzikovic, L. Aryan, and M. Eghbali, “Connecting Sex Differences, Estrogen Signaling, and microRNAs in Cardiac Fibrosis,” Journal of Molecular Medicine (Berl) 97, no. 10 (2019): 1385–1398.

[146] Y. Xu, I. A. Arenas, S. J. Armstrong, and S. T. Davidge, “Estrogen Modulation of Left Ventricular Remodeling in the Aged Heart,” Cardiovascular Research 57, no. 2 (2003): 388–394.

[147] H. Wang, X. Sun, M. S. Lin, C. M. Ferrario, H. Van Remmen, and L. Groban, “G Protein-coupled Estrogen Receptor (GPER) Deficiency Induces Cardiac Remodeling Through Oxidative Stress,” Translational Research 199 (2018): 39–51.

[148] A. Jovanović, “Ageing, Gender and Cardiac Sarcolemmal K(ATP) Channels,” Journal of Pharmacy and Pharmacology 58, no. 12 (2006): 1585–1589.

[149] D. Xing, S. Nozell, Y. F. Chen, F. Hage, and S. Oparil, “Estrogen and Mechanisms of Vascular Protection,” Arteriosclerosis, Thrombosis, and Vascular Biology 29, no. 3 (2009): 289–295.

[150] D. Wang, S. Oparil, Y. F. Chen, et al., “Estrogen Treatment Abrogates Neointima Formation in human C-reactive Protein Transgenic Mice,” Arteriosclerosis, Thrombosis, and Vascular Biology 25, no. 10 (2005): 2094–2099.

[151] X. Xu, B. Wang, C. Ren, et al., “Recent Progress in Vascular Aging: Mechanisms and Its Role in Age-related Diseases,” Aging and Disease 8, no. 4 (2017): 486–505.

[152] K. L. Hildreth, W. M. Kohrt, and K. L. Moreau, “Oxidative Stress Contributes to Large Elastic Arterial Stiffening Across the Stages of the Menopausal Transition,” Menopause 21, no. 6 (2014): 624–632.

[153] V. Dam, Y. T. van der Schouw, N. C. Onland-Moret, et al., “Association of Menopausal Characteristics and Risk of Coronary Heart Disease: A pan-European Case-cohort Analysis,” International Journal of Epidemiology 48, no. 4 (2019): 1275–1285.

[154] T. Muka, C. Oliver-Williams, S. Kunutsor, et al., “Association of Age at Onset of Menopause and Time Since Onset of Menopause with Cardiovascular Outcomes, Intermediate Vascular Traits, and all-Cause Mortality: A Systematic Review and Meta-analysis,” JAMA Cardiology 1, no. 7 (2016): 767–776.

[155] D. Appiah, P. J. Schreiner, E. W. Demerath, L. R. Loehr, P. P. Chang, and A. R. Folsom, “Association of Age at Menopause with Incident Heart Failure: A Prospective Cohort Study and Meta-Analysis,” Journal of the American Heart Association 5, no. 8 (2016): e003769.

[156] M. K. Son, N. K. Lim, J. Y. Lim, et al., “Difference in Blood Pressure Between Early and Late Menopausal Transition Was Significant in Healthy Korean Women,” BMC Womens Health 15 (2015): 64.

[157] S. R. El Khoudary, R. P. Wildman, K. Matthews, R. C. Thurston, J. T. Bromberger, and K. Sutton-Tyrrell, “Progression Rates of Carotid Intima-media Thickness and Adventitial Diameter During the Menopausal Transition,” Menopause 20, no. 1 (2013): 8–14.

[158] Z. A. Khan, I. Janssen, J. K. Mazzarelli, et al., “Serial Studies in Subclinical Atherosclerosis during Menopausal Transition (From the Study of Women's Health Across the Nation),” American Journal of Cardiology 122, no. 7 (2018): 1161–1168.

[159] P. Scheltens, B. De Strooper, M. Kivipelto, et al., “Alzheimer's Disease,” Lancet 397, no. 10284 (2021): 1577–1590.

[160] J. Xiong, S. S. Kang, Z. Wang, et al., “FSH Blockade Improves Cognition in Mice With Alzheimer's Disease,” Nature 603, no. 7901 (2022): 470–476.

[161] X. Gallart-Palau, B. S. Lee, S. S. Adav, et al., “Gender Differences in White Matter Pathology and Mitochondrial Dysfunction in Alzheimer's Disease With Cerebrovascular Disease,” Molecular Brain 9 (2016): 27.

[162] L. Mosconi, V. Berti, C. Quinn, et al., “Perimenopause and Emergence of an Alzheimer's Bioenergetic Phenotype in Brain and Periphery,” PLoS ONE 12, no. 10 (2017): e0185926.

[163] M. S. Uddin, M. M. Rahman, M. Jakaria, et al., “Estrogen Signaling in Alzheimer's Disease: Molecular Insights and Therapeutic Targets for Alzheimer's Dementia,” Molecular Neurobiology 57, no. 6 (2020): 2654–2670.

[164] A. Hestiantoro, M. Wiwie, A. Shadrina, N. Ibrahim, and J. S. Purba, “FSH to Estradiol Ratio Can be Used as Screening Method for Mild Cognitive Impairment in Postmenopausal Women,” Climacteric 20, no. 6 (2017): 577–582.

[165] J. Ryan, J. Scali, I. Carrière, et al., “Impact of a Premature Menopause on Cognitive Function in Later Life,” Bjog 121, no. 13 (2014): 1729–1739.

[166] H. Xi, J. Gan, S. Liu, et al., “Reproductive Factors and Cognitive Impairment in Natural Menopausal Women: A Cross-sectional Study,” Frontiers in Endocrinology (Lausanne) 13 (2022): 893901.

[167] W. A. Rocca, C. M. Lohse, C. Y. Smith, J. A. Fields, M. M. Machulda, and M. M. Mielke, “Association of Premenopausal Bilateral Oophorectomy with Cognitive Performance and Risk of Mild Cognitive Impairment,” JAMA Network Open 4, no. 11 (2021): e2131448.

[168] J. C. Jurado-Coronel, R. Cabezas, M. F. Ávila Rodríguez, V. Echeverria, L. M. García-Segura, and G. E. Barreto, “Sex Differences in Parkinson's Disease: Features on Clinical Symptoms, Treatment Outcome, Sexual Hormones and Genetics,” Frontiers in Neuroendocrinology 50 (2018): 18–30.

[169] X. Z. Li, C. Y. Sui, Q. Chen, Y. S. Zhuang, H. Zhang, and X. P. Zhou, “The Effects and Mechanism of Estrogen on Rats With Parkinson's Disease in Different Age Groups,” American Journal of Translational Research 8, no. 10 (2016): 4134–4146.

[170] A. I. Rodriguez-Perez, R. Valenzuela, B. Villar-Cheda, M. J. Guerra, J. L. Lanciego, and J. L. Labandeira-Garcia, “Estrogen and Angiotensin Interaction in the Substantia nigra. Relevance to Postmenopausal Parkinson's Disease,” Experimental Neurology 224, no. 2 (2010): 517–526.

[171] C. D. J. Kusters, K. C. Paul, A. Duarte Folle, et al., “Increased Menopausal Age Reduces the Risk of Parkinson's Disease: A Mendelian Randomization Approach,” Movement Disorders 36, no. 10 (2021): 2264–2272.

[172] R. Yadav, G. Shukla, V. Goyal, S. Singh, and M. Behari, “A Case Control Study of Women With Parkinson's Disease and Their Fertility Characteristics,” Journal of the Neurological Sciences 319, no. 1–2 (2012): 135–138.

[173] D. Frentzel, G. Judanin, O. Borozdina, J. Klucken, J. Winkler, and J. C. M. Schlachetzki, “Increase of Reproductive Life Span Delays Age of Onset of Parkinson's Disease,” Frontiers in Neurology 8 (2017): 397.

[174] M. Nitkowska, M. Czyżyk, and A. Friedman, “Reproductive Life Characteristics in Females Affected With Parkinson's disease and in Healthy Control Subjects—a Comparative Study on Polish Population,” Neurologia I Neurochirurgia Polska 48, no. 5 (2014): 322–327.

[175] M. Canonico, G. Pesce, A. Bonaventure, et al., “Increased Risk of Parkinson's Disease in Women After Bilateral Oophorectomy,” Movement Disorders 36, no. 7 (2021): 1696–1700.

[176] A. Chandra and J. Rajawat, “Skeletal Aging and Osteoporosis: Mechanisms and Therapeutics,” International Journal of Molecular Sciences 22, no. 7 (2021): 3553.

[177] P. Pivonka, J. L. Calvo-Gallego, S. Schmidt, and J. Martínez-Reina, “Advances in Mechanobiological Pharmacokinetic-pharmacodynamic Models of Osteoporosis Treatment—Pathways to Optimise and Exploit Existing Therapies,” Bone 186 (2024): 117140.

[178] V. Gopinath, “Osteoporosis,” Medical Clinics of North America 107, no. 2 (2023): 213–225.

[179] B. L. Riggs and L. J. Melton 3rd, “The Prevention and Treatment of Osteoporosis,” New England Journal of Medicine 327, no. 9 (1992): 620–627.

[180] S. J. Curry, A. H. Krist, D. K. Owens, et al., “Screening for Osteoporosis to Prevent Fractures: US Preventive Services Task Force Recommendation Statement,” Jama 319, no. 24 (2018): 2521–2531.

[181] Management of Osteoporosis in Postmenopausal Women: The 2021 Position Statement of The North American Menopause Society. Menopause 28, no. 9 (2021): 973–997.

[182] S. Y. Ahn, Y. J. Choi, J. Kim, G. J. Ko, Y. J. Kwon, and K. Han, “The Beneficial Effects of Menopausal Hormone Therapy on Renal Survival in Postmenopausal Korean Women From a Nationwide Health Survey,” Scientific Reports 11, no. 1 (2021): 15418.

[183] S. Masrouri, D. Alijanzadeh, M. Amiri, F. Azizi, and F. Hadaegh, “Predictors of Decline in Kidney Function in the General Population: A Decade of Follow-up From the Tehran Lipid and Glucose Study,” Annals of Medicine 55, no. 1 (2023): 2216020.

[184] E. C. Cevik, C. T. Erel, I. B. Ozcivit Erkan, et al., “Chronic Kidney Disease and Menopausal Health: An EMAS Clinical Guide,” Maturitas 192 (2025): 108145.

[185] D. Qian, Z. F. Wang, Y. C. Cheng, R. Luo, S. W. Ge, and G. Xu, “Early Menopause May Associate with a Higher Risk of CKD and all-Cause Mortality in Postmenopausal Women: An Analysis of NHANES, 1999–2014,” Frontiers in Medicine (Lausanne) 9 (2022): 823835.

[186] P. Kur, A. Kolasa-Wołosiuk, K. Misiakiewicz-Has, and B. Wiszniewska, “Sex Hormone-Dependent Physiology and Diseases of Liver,” International Journal of Environmental Research and Public Health 17, no. 8 (2020): 2620.

[187] Y. Fukata, X. Yu, H. Imachi, et al., “17β-Estradiol Regulates Scavenger Receptor Class BI Gene Expression via Protein Kinase C in Vascular Endothelial Cells,” Endocrine 46, no. 3 (2014): 644–650.

[188] R. A. Kireev, A. C. Tresguerres, C. Garcia, et al., “Hormonal Regulation of Pro-inflammatory and Lipid Peroxidation Processes in Liver of Old Ovariectomized Female Rats,” Biogerontology 11, no. 2 (2010): 229–243.

[189] Y. Gutierrez-Grobe, G. Ponciano-Rodríguez, M. H. Ramos, M. Uribe, and N. Méndez-Sánchez, “Prevalence of Non Alcoholic Fatty Liver Disease in Premenopausal, Posmenopausal and Polycystic Ovary Syndrome Women. The Role of Estrogens,” Annals of Hepatology 9, no. 4 (2010): 402–409.

[190] X. Wang, Y. Lu, E. Wang, et al., “Hepatic Estrogen Receptor α Improves Hepatosteatosis Through Upregulation of Small Heterodimer Partner,” Journal of Hepatology 63, no. 1 (2015): 183–190.

[191] R. de Mutsert, K. Gast, R. Widya, et al., “Associations of Abdominal Subcutaneous and Visceral Fat With Insulin Resistance and Secretion Differ between Men and Women: The Netherlands Epidemiology of Obesity Study,” Metabolic Syndrome and Related Disorders 16, no. 1 (2018): 54–63.

[192] I. Lambrinoudaki, S. A. Paschou, E. Armeni, and D. G. Goulis, “The Interplay Between Diabetes Mellitus and Menopause: Clinical Implications,” Nature Reviews Endocrinology 18, no. 10 (2022): 608–622.

[193] J. S. Brand, Y. T. van der Schouw, N. C. Onland-Moret, et al., “Age at Menopause, Reproductive Life Span, and Type 2 Diabetes Risk: Results From the EPIC-InterAct Study,” Diabetes Care 36, no. 4 (2013): 1012–1019.

[194] E. S. LeBlanc, K. Kapphahn, H. Hedlin, et al., “Reproductive History and Risk of Type 2 Diabetes Mellitus in Postmenopausal Women: Findings From the Women's Health Initiative,” Menopause 24, no. 1 (2017): 64–72.

[195] S. R. Mishra, M. Waller, H. F. Chung, and G. D. Mishra, “Epidemiological Studies of the Association Between Reproductive Lifespan Characteristics and Risk of Type 2 Diabetes and Hypertension: A Systematic Review,” Maturitas 155 (2022): 14–23.

[196] M. J. Herring, M. V. Avdalovic, B. Lasley, L. F. Putney, and D. M. Hyde, “Elderly Female Rhesus Macaques Preserve Lung Alveoli with Estrogen/Progesterone Therapy,” The Anatomical Record (Hoboken) 299, no. 7 (2016): 973–978.

[197] D. Massaro and G. D. Massaro, “Toward Therapeutic Pulmonary Alveolar Regeneration in Humans,” Proceedings of the American Thoracic Society 3, no. 8 (2006): 709–712.

[198] P. J. Barnes, “Oxidative Stress-based Therapeutics in COPD,” Redox Biology 33 (2020): 101544.

[199] M. R. Hayatbakhsh, J. M. Najman, M. J. O'Callaghan, G. M. Williams, A. Paydar, and A. Clavarino, “Association Between Smoking and respiratory Function Before and After Menopause,” Lung 189, no. 1 (2011): 65–71.

[200] A. F. Amaral, D. P. Strachan, F. Gómez Real, P. G. Burney, and D. L. Jarvis, “Lower Lung Function Associates With Cessation of Menstruation: UK Biobank Data,” European Respiratory Journal 48, no. 5 (2016): 1288–1297.

[201] R. Tang, A. Fraser, and M. C. Magnus, “Female Reproductive History in Relation to Chronic Obstructive Pulmonary Disease and Lung Function in UK biobank: A Prospective Population-based Cohort Study,” BMJ Open 9, no. 10 (2019): e030318.

[202] X. Xu, M. Jones, and G. D. Mishra, “Age at Natural Menopause and Development of Chronic Conditions and Multimorbidity: Results From an Australian Prospective Cohort,” Human Reproduction 35, no. 1 (2020): 203–211.

[203] A. Grimm, A. G. Mensah-Nyagan, and A. Eckert, “Alzheimer, Mitochondria and Gender,” Neuroscience and Biobehavioral Reviews 67 (2016): 89–101.

[204] Z. Amtul, L. Wang, D. Westaway, and R. F. Rozmahel, “Neuroprotective Mechanism Conferred by 17beta-estradiol on the Biochemical Basis of Alzheimer's Disease,” Neuroscience 169, no. 2 (2010): 781–786.

[205] H. Huque, R. Eramudugolla, B. Chidiac, et al., “Could Country-Level Factors Explain Sex Differences in Dementia Incidence and Prevalence? A Systematic Review and Meta-Analysis,” Journal of Alzheimer's Disease 91, no. 4 (2023): 1231–1241.

[206] R. Bove, E. Secor, L. B. Chibnik, et al., “Age at Surgical Menopause Influences Cognitive Decline and Alzheimer Pathology in Older Women,” Neurology 82, no. 3 (2014): 222–229.

[207] M. J. Armstrong and M. S. Okun, “Diagnosis and Treatment of Parkinson Disease: A Review,” Jama 323, no. 6 (2020): 548–560.

[208] J. L. Labandeira-Garcia, A. I. Rodriguez-Perez, R. Valenzuela, M. A. Costa-Besada, and M. J. Guerra, “Menopause and Parkinson's Disease. Interaction Between Estrogens and Brain Renin-angiotensin System in Dopaminergic Degeneration,” Frontiers in Neuroendocrinology 43 (2016): 44–59.

[209] B. F. Boyce and L. Xing, “Functions of RANKL/RANK/OPG in Bone Modeling and Remodeling,” Archives of Biochemistry and Biophysics 473, no. 2 (2008): 139–146.

[210] J. Iqbal, L. Sun, and M. Zaidi, “Commentary-FSH and Bone 2010: Evolving Evidence,” European Journal of Endocrinology 163, no. 1 (2010): 173–176.

[211] Epidemiology of osteoporosis and fragility fractures, https://www.osteoporosis.foundation/facts-statistics/epidemiology-of-osteoporosis-and-fragility-fractures.

[212] M. van Oostwaard. Osteoporosis and the Nature of Fragility Fracture: An Overview. In Fragility Fracture Nursing: Holistic Care and Management of the Orthogeriatric Patient, edited by K. Hertz and J. Santy-Tomlinson (Cham (CH): Springer, 2018). Copyright 2018, The Editor(s)(if applicable) and the Author(s). This book is an open access publication., 2018.

[213] P. Romagnani, G. Remuzzi, R. Glassock, et al., “Chronic Kidney Disease,” Nature Reviews Disease Primers 3 (2017): 17088.

[214] J. Neugarten, A. Acharya, J. Lei, and S. Silbiger, “Selective Estrogen Receptor Modulators Suppress Mesangial Cell Collagen Synthesis,” American Journal of Physiology Renal Physiology 279, no. 2 (2000): F309–F318.

[215] V. H. Urbieta-Caceres, F. A. Syed, J. Lin, et al., “Age-dependent Renal Cortical Microvascular Loss in Female Mice,” American Journal of Physiology Endocrinology and Metabolism 302, no. 8 (2012): E979–E986.

[216] N. R. Hill, S. T. Fatoba, J. L. Oke, et al., “Global Prevalence of Chronic Kidney Disease—A Systematic Review and Meta-Analysis,” PLoS ONE 11, no. 7 (2016): e0158765.

[217] M. Chin, M. Isono, K. Isshiki, et al., “Estrogen and Raloxifene, a Selective Estrogen Receptor Modulator, Ameliorate Renal Damage in db/db Mice,” American Journal of Pathology 166, no. 6 (2005): 1629–1636.

[218] Z. M. Younossi, G. Marchesini, H. Pinto-Cortez, and S. Petta, “Epidemiology of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis: Implications for Liver Transplantation,” Transplantation 103, no. 1 (2019): 22–27.

[219] C. D. Byrne and G. Targher, “NAFLD: A Multisystem Disease,” Journal of Hepatology 62, no. 1 Suppl (2015): S47–S64.

[220] N. C. Salvoza, P. J. Giraudi, C. Tiribelli, and N. Rosso, “Sex Differences in Non-alcoholic Fatty Liver Disease: Hints for Future Management of the Disease,” Exploration of Medicine 1, no. 2 (2020): 51–74.

[221] Y. Imbert-Fernandez, B. F. Clem, J. O'Neal, et al., “Estradiol Stimulates Glucose Metabolism via 6-phosphofructo-2-kinase (PFKFB3),” Journal of Biological Chemistry 289, no. 13 (2014): 9440–9448.

[222] M. Yang, F. Ma, and M. Guan, “Role of Steroid Hormones in the Pathogenesis of Nonalcoholic Fatty Liver Disease,” Metabolites 11, no. 5 (2021): 320.

[223] B. T. Palmisano, L. Zhu, and J. M. Stafford, “Role of Estrogens in the Regulation of Liver Lipid Metabolism,” Advances in Experimental Medicine and Biology 1043 (2017): 227–256.

[224] K. Pafili, S. A. Paschou, E. Armeni, S. A. Polyzos, D. G. Goulis, and I. Lambrinoudaki, “Non-alcoholic Fatty Liver Disease Through the Female Lifespan: The Role of Sex Hormones,” Journal of Endocrinological Investigation 45, no. 9 (2022): 1609–1623.

[225] K. Matsuo, M. R. Gualtieri, S. S. Cahoon, et al., “Surgical Menopause and Increased Risk of Nonalcoholic Fatty Liver Disease in Endometrial Cancer,” Menopause 23, no. 2 (2016): 189–196.

[226] J. S. Klair, J. D. Yang, M. F. Abdelmalek, et al., “A Longer Duration of Estrogen Deficiency Increases Fibrosis Risk Among Postmenopausal Women With Nonalcoholic Fatty Liver Disease,” Hepatology 64, no. 1 (2016): 85–91.

[227] M. Von-Hafe, M. Borges-Canha, C. Vale, et al., “Nonalcoholic Fatty Liver Disease and Endocrine Axes-A Scoping Review,” Metabolites 12, no. 4 (2022): 298.

[228] J. D. Yang, M. F. Abdelmalek, H. Pang, et al., “Gender and Menopause Impact Severity of Fibrosis Among Patients With Nonalcoholic Steatohepatitis,” Hepatology 59, no. 4 (2014): 1406–1414.

[229] A. Suzuki and M. F. Abdelmalek, “Nonalcoholic Fatty Liver Disease in Women,” Womens Health (London) 5, no. 2 (2009): 191–203.

[230] S. A. Paschou, K. I. Athanasiadou, and N. Papanas, “Menopausal Hormone Therapy in Women With Type 2 Diabetes Mellitus: An Updated Review,” Diabetes Therapy 15, no. 4 (2024): 741–748.

[231] S. K. Park, S. D. Harlow, H. Zheng, et al., “Association Between Changes in Oestradiol and Follicle-stimulating Hormone Levels During the Menopausal Transition and Risk of Diabetes,” Diabetic Medicine 34, no. 4 (2017): 531–538.

[232] I. A. Yang, C. R. Jenkins, and S. S. Salvi, “Chronic Obstructive Pulmonary Disease in Never-smokers: Risk Factors, Pathogenesis, and Implications for Prevention and Treatment,” The Lancet Respiratory Medicine 10, no. 5 (2022): 497–511.

[233] V. Sathish, Y. N. Martin, and Y. S. Prakash, “Sex Steroid Signaling: Implications for Lung Diseases,” Pharmacology & Therapeutics 150 (2015): 94–108.

[234] D. Massaro and G. D. Massaro, “Estrogen Regulates Pulmonary Alveolar Formation, Loss, and Regeneration in Mice,” American Journal of Physiology Lung Cellular and Molecular Physiology 287, no. 6 (2004): L1154–L1159.

[235] B. Xie, Q. Chen, Z. Dai, C. Jiang, and X. Chen, “Progesterone (P4) Ameliorates Cigarette Smoke-induced Chronic Obstructive Pulmonary Disease (COPD),” Molecular Medicine 30, no. 1 (2024): 123.

[236] F. G. Real, C. Svanes, E. R. Omenaas, et al., “Lung Function, respiratory Symptoms, and the Menopausal Transition,” Journal of Allergy and Clinical Immunology 121, no. 1 (2008): 72–80.e3.

[237] N. Samad, H. H. Nguyen, D. Scott, P. R. Ebeling, and F. Milat, “Musculoskeletal Health in Premature Ovarian Insufficiency. Part One: Muscle,” Seminars in Reproductive Medicine 38, no. 4–05 (2020): 277–288.

[238] S. Elliot, P. Catanuto, P. Fernandez, et al., “Subtype Specific Estrogen Receptor Action Protects Against Changes in MMP-2 Activation in Mouse Retinal Pigmented Epithelial Cells,” Experimental Eye Research 86, no. 4 (2008): 653–660.

[239] R. Pinaud and L. A. Tremere, “Control of central Auditory Processing by a Brain-generated Oestrogen,” Nature Reviews Neuroscience 13, no. 8 (2012): 521–527.

[240] T. T. Williamson, B. Ding, X. Zhu, and R. D. Frisina, “Hormone Replacement Therapy Attenuates Hearing Loss: Mechanisms Involving Estrogen and the IGF-1 Pathway,” Aging Cell 18, no. 3 (2019): e12939.

[241] Z. Y. Feng, T. L. Huang, X. R. Li, et al., “17β-Estradiol Promotes Angiogenesis of Stria Vascular in Cochlea of C57BL/6J Mice,” European Journal of Pharmacology 913 (2021): 174642.

[242] M. P. Brincat, Y. M. Baron, and R. Galea, “Estrogens and the Skin,” Climacteric 8, no. 2 (2005): 110–123.

[243] C. M. Gameiro, F. Romão, and C. Castelo-Branco, “Menopause and Aging: Changes in the Immune System–a Review,” Maturitas 67, no. 4 (2010): 316–320.

[244] C. Gameiro and F. Romao, “Changes in the Immune System During Menopause and Aging,” Frontiers in Bioscience (Elite Ed) 2, no. 4 (2010): 1299–1303.

[245] J. S. Smith, A. Melendy, R. K. Rana, and J. M. Pimenta, “Age-specific Prevalence of Infection With human Papillomavirus in Females: A Global Review,” Journal of Adolescent Health 43, no. 4 Suppl (2008): S5–S25. S25.e1-41.

[246] N. Andany, V. L. Kennedy, M. Aden, and M. Loutfy, “Perspectives on Menopause and Women With HIV,” International Journal of Women's Health 8 (2016): 1–22.

[247] M. K. Desai and R. D. Brinton, “Autoimmune Disease in Women: Endocrine Transition and Risk across the Lifespan,” Frontiers in Endocrinology (Lausanne) 10 (2019): 265.

[248] K. C. E. Drechsel, M. C. F. Pilon, F. Stoutjesdijk, et al., “Reproductive Ability in Survivors of Childhood, Adolescent, and Young Adult Hodgkin Lymphoma: A Review,” Human Reproduction Update 29, no. 4 (2023): 486–517.

[249] A. La Marca, E. Spada, G. Sighinolfi, et al., “Age-specific Nomogram for the Decline in Antral Follicle Count throughout the Reproductive Period,” Fertility and Sterility 95, no. 2 (2011): 684–688.

[250] J. G. Bentzen, J. L. Forman, T. H. Johannsen, A. Pinborg, E. C. Larsen, and A. N. Andersen, “Ovarian Antral Follicle Subclasses and anti-mullerian Hormone During Normal Reproductive Aging,” Journal of Clinical Endocrinology and Metabolism 98, no. 4 (2013): 1602–1611.

[251] T. Kelsey, “Models and Biomarkers for Ovarian Ageing,” Sub-Cellular Biochemistry 103 (2023): 185–199.

[252] S. Yureneva, V. Averkova, D. Silachev, et al., “Searching for Female Reproductive Aging and Longevity Biomarkers,” Aging (Albany NY) 13, no. 12 (2021): 16873–16894.

[253] S. Sinha, A. Sharan, and S. Sinha, “Anti-Mullerian Hormone as a Marker of Ovarian Reserve and Function,” Cureus 14, no. 9 (2022): e29214.

[254] C. A. Bastos, K. Oppermann, S. C. Fuchs, G. B. Donato, and P. M. Spritzer, “Determinants of Ovarian Volume in Pre-, Menopausal Transition, and Post-menopausal Women: A Population-based Study,” Maturitas 53, no. 4 (2006): 405–412.

[255] M. Giacobbe, A. M. Pinto-Neto, L. H. Costa-Paiva, and E. Z. Martinez, “Ovarian Volume, Age, and Menopausal Status,” Menopause 11, no. 2 (2004): 180–185.

[256] E. J. Pavlik, P. D. DePriest, H. H. Gallion, et al., “Ovarian Volume Related to Age,” Gynecologic Oncology 77, no. 3 (2000): 410–412.

[257] E. Granger and R. Tal, “Anti-Müllerian Hormone and Its Predictive Utility in Assisted Reproductive Technologies Outcomes,” Clinical Obstetrics and Gynecology 62, no. 2 (2019): 238–256.

[258] Y. S. Yang, M. H. Hur, S. Y. Kim, and K. Young, “Correlation Between Sonographic and Endocrine Markers of Ovarian Aging as Predictors for Late Menopausal Transition,” Menopause 18, no. 2 (2011): 138–145.

[259] E. W. Freeman, M. D. Sammel, H. Lin, and C. R. Gracia, “Anti-mullerian Hormone as a Predictor of Time to Menopause in Late Reproductive Age Women,” Journal of Clinical Endocrinology and Metabolism 97, no. 5 (2012): 1673–1680.

[260] S. Nair, J. C. Slaughter, J. G. Terry, et al., “Anti-mullerian Hormone (AMH) Is Associated With Natural Menopause in a Population-based Sample: The CARDIA Women's Study,” Maturitas 81, no. 4 (2015): 493–498.

[261] I. F. Reijnders, W. L. Nelen, J. IntHout, A. E. van Herwaarden, D. D. Braat, and K. Fleischer, “The Value of Anti-Müllerian Hormone in Low and Extremely Low Ovarian Reserve in Relation to Live Birth After in Vitro Fertilization,” European Journal of Obstetrics, Gynecology, and Reproductive Biology 200 (2016): 45–50.

[262] M. M. Hopeman, K. E. Cameron, M. Prewitt, et al., “A Predictive Model for Chemotherapy-related Diminished Ovarian Reserve in Reproductive-age Women,” Fertility and Sterility 115, no. 2 (2021): 431–437.

[263] J. S. E. Laven and Y. V. Louwers, “Can We Predict Menopause and Premature Ovarian Insufficiency?,” Fertility and Sterility 121, no. 5 (2024): 737–741.

[264] R. Tal and D. B. Seifer, “Ovarian Reserve Testing: A User's Guide,” American Journal of Obstetrics and Gynecology 217, no. 2 (2017): 129–140.

[265] J. Wen, K. Huang, X. Du, et al., “Can Inhibin B Reflect Ovarian Reserve of Healthy Reproductive Age Women Effectively?,” Frontiers in Endocrinology (Lausanne) 12 (2021): 626534.

[266] C. Zhu, W. Luo, Z. Li, et al., “New Theca-cell Marker Insulin-Like Factor 3 Is Associated With Premature Ovarian Insufficiency,” Fertility and Sterility 115, no. 2 (2021): 455–462.

[267] A. Z. Steiner, D. Pritchard, F. Z. Stanczyk, et al., “Association between Biomarkers of Ovarian Reserve and Infertility among Older Women of Reproductive Age,” Jama 318, no. 14 (2017): 1367–1376.

[268] Z. Yu, W. Peng, F. Li, et al., “Integrated Metabolomics and Transcriptomics to Reveal Biomarkers and Mitochondrial Metabolic Dysregulation of Premature Ovarian Insufficiency,” Frontiers in Endocrinology (Lausanne) 14 (2023): 1280248.

[269] J. Hao, L. Liu, B. Chang, et al., “Blood-detected Mitochondrial Biomarker NSUN4: A Potential Indicator of Ovarian Aging,” Experimental Gerontology 208 (2025): 112825.

[270] D. Valerio, A. Luddi, V. De Leo, D. Labella, S. Longobardi, and P. Piomboni, “SA1/SA2 cohesion Proteins and SIRT1-NAD+ Deacetylase Modulate Telomere Homeostasis in Cumulus Cells and Are Eligible Biomarkers of Ovarian Aging,” Human Reproduction 33, no. 5 (2018): 887–894.

[271] J. Wu, X. Zhao, Y. Fang, et al., “GPD1L-Mediated Glycerophospholipid Metabolism Dysfunction in Women with Diminished Ovarian Reserve: Insights from Pseudotargeted Metabolomic Analysis of Follicular Fluid,” Cell Proliferation 58, no. 9 (2025): e70024.

[272] X. Li, X. Chen, and H. Guo, “Plasminogen Activator Inhibitor 1 Is a Novel Predictor in human Serum/Follicular Fluid for Diminished Ovarian Reserve,” BMC Womens Health 25, no. 1 (2025): 210.

[273] X. Meng, L. Peng, X. Wei, and S. Li, “FOXO3 is a Potential Biomarker and Therapeutic Target for Premature Ovarian Insufficiency (Review),” Molecular Medicine Reports 27, no. 2 (2023).

[274] J. Lin, J. Zheng, H. Zhang, et al., “Cytochrome P450 family Proteins as Potential Biomarkers for Ovarian Granulosa Cell Damage in Mice With Premature Ovarian Failure,” International Journal of Clinical and Experimental Pathology 11, no. 8 (2018): 4236–4246.

[275] M. J. Park, J. W. Ahn, K. H. Kim, et al., “Prediction of Ovarian Aging Using Ovarian Expression of BMP15, GDF9, and C-KIT,” Experimental Biology and Medicine (Maywood, NJ) 245, no. 8 (2020): 711–719.

[276] D. Zhang, J. Lv, R. Tang, et al., “Association of Exosomal microRNAs in human Ovarian Follicular Fluid With Oocyte Quality,” Biochemical and Biophysical Research Communications 534 (2021): 468–473.

[277] B. M. Zanini, B. M. de Avila, D. N. Garcia, et al., “Dynamics of Serum Exosome microRNA Profile Altered by Chemically Induced Estropause and Rescued by Estrogen Therapy in Female Mice,” Geroscience 46, no. 6 (2024): 5891–5909.

[278] A. Rapani, D. Nikiforaki, D. Karagkouni, et al., “Reporting on the Role of miRNAs and Affected Pathways on the Molecular Backbone of Ovarian Insufficiency: A Systematic Review and Critical Analysis Mapping of Future Research,” Frontiers in Cell and Developmental Biology 8 (2020): 590106.

[279] W. Ju, S. Zhao, H. Wu, et al., “miR-6881-3p Contributes to Diminished Ovarian Reserve by Regulating Granulosa Cell Apoptosis by Targeting SMAD4,” Reproductive Biology and Endocrinology [Electronic Resource]: RB&E 22, no. 1 (2024): 17.

[280] N. Panay, R. A. Anderson, A. Bennie, et al., “Evidence-based Guideline: Premature Ovarian Insufficiency,” Fertility and Sterility 123, no. 2 (2025): 221–236.

[281] H. Liu, X. Wei, Y. Sha, et al., “Whole-exome Sequencing in Patients With Premature Ovarian Insufficiency: Early Detection and Early Intervention,” Journal of Ovarian Research 13, no. 1 (2020): 114.

[282] E. J. Zaniker, M. Zhang, L. Hughes, et al., “Shear Wave Elastography to Assess Stiffness of the human Ovary and Other Reproductive Tissues Across the Reproductive Lifespan in Health and Disease†,” Biology of Reproduction 110, no. 6 (2024): 1100–1114.

[283] H. Miao, S. Liu, Z. Wang, et al., “Artificial Intelligence-derived Retinal Age Gap as a Marker for Reproductive Aging in Women,” npj Digital Medicine 8, no. 1 (2025): 367.

[284] S. Wei, W. Tang, D. Chen, et al., “Multiomics Insights Into the Female Reproductive Aging,” Ageing Research Reviews 95 (2024): 102245.

[285] M. Wu, W. Tang, Y. Chen, et al., “Spatiotemporal Transcriptomic Changes of human Ovarian Aging and the Regulatory Role of FOXP1,” Nature Aging 4, no. 4 (2024): 527–545.

[286] E. Babayev and F. E. Duncan, “Age-associated Changes in Cumulus Cells and Follicular Fluid: The Local Oocyte Microenvironment as a Determinant of Gamete Quality,” Biology of Reproduction 106, no. 2 (2022): 351–365.

[287] J. Huang, P. Chen, L. Jia, et al., “Multi-Omics Analysis Reveals Translational Landscapes and Regulations in Mouse and Human Oocyte Aging,” Advanced Science (Weinh) 10, no. 26 (2023): e2301538.

[288] C. Lu, C. Qin, Z. Fu, et al., “Metabolic Dysregulation in Patients With Premature Ovarian Insufficiency Revealed by Integrated Transcriptomic, Methylomic and Metabolomic Analyses,” Clinical and Translational Medicine 12, no. 10 (2022): e1006.

[289] R. AlSaad, A. Abd-Alrazaq, F. Choucair, A. Ahmed, S. Aziz, and J. Sheikh, “Harnessing Artificial Intelligence to Predict Ovarian Stimulation Outcomes in in Vitro Fertilization: Scoping Review,” Journal of Medical Internet Research [Electronic Resource] 26 (2024): e53396.

[290] T. Ding, W. Ren, T. Wang, et al., “Assessment and Quantification of Ovarian Reserve on the Basis of Machine Learning Models,” Frontiers in Endocrinology (Lausanne) 14 (2023): 1087429.

[291] X. Zhang, Y. Xing, K. Sun, and Y. Guo, “OmiEmbed: A Unified Multi-Task Deep Learning Framework for Multi-Omics Data,” Cancers (Basel) 13, no. 12 (2021): 3047.

[292] Z. Nash and M. Davies, “Premature Ovarian Insufficiency,” Bmj 384 (2024): e077469.

[293] J. E. Rossouw, G. L. Anderson, R. L. Prentice, et al., “Risks and Benefits of Estrogen plus Progestin in Healthy Postmenopausal Women: Principal Results from the Women's Health Initiative Randomized Controlled Trial,” Jama 288, no. 3 (2002): 321–333.

[294] M. Liu, Y. Yin, X. Ye, et al., “Resveratrol Protects Against Age-associated Infertility in Mice,” Human Reproduction 28, no. 3 (2013): 707–717.

[295] N. Li and L. Liu, “Mechanism of Resveratrol in Improving Ovarian Function in a Rat Model of Premature Ovarian Insufficiency,” Journal of Obstetrics and Gynaecology Research 44, no. 8 (2018): 1431–1438.

[296] R. S. Said, E. M. Mantawy, and E. El-Demerdash, “Mechanistic Perspective of Protective Effects of Resveratrol Against Cisplatin-induced Ovarian Injury in Rats: Emphasis on Anti-inflammatory and Anti-apoptotic Effects,” Naunyn-Schmiedebergs Archives of Pharmacology 392, no. 10 (2019): 1225–1238.

[297] Y. Herrero, C. Velázquez, N. Pascuali, et al., “Resveratrol Alleviates Doxorubicin-induced Damage in Mice Ovary,” Chemico-Biological Interactions 376 (2023): 110431.

[298] J. Liang, F. Huang, X. Hao, P. Zhang, and R. Chen, “Nicotinamide Mononucleotide Supplementation Rescues Mitochondrial and Energy Metabolism Functions and Ameliorates Inflammatory States in the Ovaries of Aging Mice,” MedComm 5, no. 10 (2024): e727.

[299] P. Huang, Y. Zhou, W. Tang, et al., “Long-term Treatment of Nicotinamide Mononucleotide Improved Age-related Diminished Ovary Reserve Through Enhancing the Mitophagy Level of Granulosa Cells in Mice,” Journal of Nutritional Biochemistry 101 (2022): 108911.

[300] M. J. Bertoldo, D. R. Listijono, W. J. Ho, et al., “NAD(+) Repletion Rescues Female Fertility During Reproductive Aging,” Cell Reports 30, no. 6 (2020): 1670–1681.e7.

[301] D. Qiu, X. Hou, L. Han, X. Li, J. Ge, and Q. Wang, “Sirt2-BubR1 acetylation Pathway Mediates the Effects of Advanced Maternal Age on Oocyte Quality,” Aging Cell 17, no. 1 (2018): e12698.

[302] M. Zhang, Y. Lu, Y. Chen, Y. Zhang, and B. Xiong, “Insufficiency of Melatonin in Follicular Fluid Is a Reversible Cause for Advanced Maternal Age-related Aneuploidy in Oocytes,” Redox Biology 28 (2020): 101327.

[303] L. Zhang, Z. Zhang, J. Wang, et al., “Melatonin Regulates the Activities of Ovary and Delays the Fertility Decline in Female Animals via MT1/AMPK Pathway,” Journal of Pineal Research 66, no. 3 (2019): e12550.

[304] A. Al-Shahat, M. A. E. Hulail, N. M. M. Soliman, et al., “Melatonin Mitigates Cisplatin-Induced Ovarian Dysfunction via Altering Steroidogenesis, Inflammation, Apoptosis, Oxidative Stress, and PTEN/PI3K/Akt/mTOR/AMPK Signaling Pathway in Female Rats,” Pharmaceutics 14, no. 12 (2022): 2769.

[305] H. Tamura, M. Kawamoto, S. Sato, et al., “Long-term Melatonin Treatment Delays Ovarian Aging,” Journal of Pineal Research 62, no. 2 (2017): e12381.

[306] S. Behnam, S. Zavareh, and M. Salehnia, “Expression of Apoptosis-Related Genes in Cultured Ovarian Tissue of Mouse in Presence of Coenzyme Q(10),” Journal of Family and Reproductive Health 17, no. 2 (2023): 65–72.

[307] A. Delkhosh, M. Delashoub, A. A. Tehrani, et al., “Upregulation of FSHR and PCNA by Administration of Coenzyme Q10 on Cyclophosphamide-induced Premature Ovarian Failure in a Mouse Model,” Journal of Biochemical and Molecular Toxicology 33, no. 11 (2019): e22398.

[308] H. J. Lee, M. J. Park, B. S. Joo, et al., “Effects of Coenzyme Q10 on Ovarian Surface Epithelium-derived Ovarian Stem Cells and Ovarian Function in a 4-vinylcyclohexene Diepoxide-induced Murine Model of Ovarian Failure,” Reproductive Biology and Endocrinology [Electronic Resource]: RB&E 19, no. 1 (2021): 59.

[309] A. Ben-Meir, E. Burstein, A. Borrego-Alvarez, et al., “Coenzyme Q10 Restores Oocyte Mitochondrial Function and Fertility During Reproductive Aging,” Aging Cell 14, no. 5 (2015): 887–895.

[310] E. M. Mantawy, R. S. Said, D. H. Kassem, A. K. Abdel-Aziz, and A. M. Badr, “Novel Molecular Mechanisms Underlying the Ameliorative Effect of N-acetyl-L-cysteine Against ϒ-radiation-induced Premature Ovarian Failure in Rats,” Ecotoxicology and Environmental Safety 206 (2020): 111190.

[311] J. Liu, M. Liu, X. Ye, et al., “Delay in Oocyte Aging in Mice by the Antioxidant N-acetyl-L-cysteine (NAC),” Human Reproduction 27, no. 5 (2012): 1411–1420.

[312] X. Qin, D. Du, Q. Chen, et al., “Metformin Prevents Murine Ovarian Aging,” Aging (Albany NY) 11, no. 11 (2019): 3785–3794.

[313] F. Ellibishy, M. Tarek, M. M. Abd-Elsalam, N. Elgayar, and W. El Bakly, “Metformin Improves D-galactose Induced Premature Ovarian Insufficiency Through PI3K-Akt-FOXO3a Pathway,” Advances in Medical Sciences 69, no. 1 (2024): 70–80.

[314] Y. Yang, X. Tang, T. Yao, et al., “Metformin Protects Ovarian Granulosa Cells in Chemotherapy-induced Premature Ovarian Failure Mice Through AMPK/PPAR-γ/SIRT1 Pathway,” Scientific Reports 14, no. 1 (2024): 1447.

[315] D. A. Landry, E. Yakubovich, D. P. Cook, S. Fasih, J. Upham, and B. C. Vanderhyden, “Metformin Prevents Age-associated Ovarian Fibrosis by Modulating the Immune Landscape in Female Mice,” Science Advances 8, no. 35 (2022): eabq1475.

[316] C. W. McCloskey, D. P. Cook, B. S. Kelly, et al., “Metformin Abrogates Age-Associated Ovarian Fibrosis,” Clinical Cancer Research 26, no. 3 (2020): 632–642.

[317] W. Dai, H. Yang, B. Xu, et al., “Human Umbilical Cord-derived Mesenchymal Stem Cells (hUC-MSCs) Alleviate Excessive Autophagy of Ovarian Granular Cells Through VEGFA/PI3K/AKT/mTOR Pathway in Premature Ovarian Failure Rat Model,” Journal of Ovarian Research 16, no. 1 (2023): 198.

[318] Z. Li, M. Zhang, J. Zheng, et al., “Human Umbilical Cord Mesenchymal Stem Cell-Derived Exosomes Improve Ovarian Function and Proliferation of Premature Ovarian Insufficiency by Regulating the Hippo Signaling Pathway,” Frontiers in Endocrinology (Lausanne) 12 (2021): 711902.

[319] C. Ding, L. Zhu, H. Shen, et al., “Exosomal miRNA-17-5p Derived From human Umbilical Cord Mesenchymal Stem Cells Improves Ovarian Function in Premature Ovarian Insufficiency by Regulating SIRT7,” Stem Cells 38, no. 9 (2020): 1137–1148.

[320] Y. Zhou, J. Huang, L. Zeng, et al., “Human Mesenchymal Stem Cells Derived Exosomes Improve Ovarian Function in Chemotherapy-induced Premature Ovarian Insufficiency Mice by Inhibiting Ferroptosis Through Nrf2/GPX4 Pathway,” Journal of Ovarian Research 17, no. 1 (2024): 80.

[321] Y. Zhao, J. Ma, P. Yi, et al., “Human Umbilical Cord Mesenchymal Stem Cells Restore the Ovarian Metabolome and Rescue Premature Ovarian Insufficiency in Mice,” Stem Cell Research & Therapy 11, no. 1 (2020): 466.

[322] S. Wang, L. Yu, M. Sun, et al., “The Therapeutic Potential of Umbilical Cord Mesenchymal Stem Cells in Mice Premature Ovarian Failure,” BioMed Research International 2013 (2013): 690491.

[323] J. Li, Q. Mao, J. He, H. She, Z. Zhang, and C. Yin, “Human Umbilical Cord Mesenchymal Stem Cells Improve the Reserve Function of Perimenopausal Ovary via a Paracrine Mechanism,” Stem Cell Research & Therapy 8, no. 1 (2017): 55.

[324] H. S. Park, R. M. Chugh, A. El Andaloussi, et al., “Human BM-MSC Secretome Enhances human Granulosa Cell Proliferation and Steroidogenesis and Restores Ovarian Function in Primary Ovarian Insufficiency Mouse Model,” Scientific Reports 11, no. 1 (2021): 4525.

[325] H. Liu, C. Jiang, B. La, et al., “Human Amnion-derived Mesenchymal Stem Cells Improved the Reproductive Function of Age-related Diminished Ovarian Reserve in Mice Through Ampk/FoxO3a Signaling Pathway,” Stem Cell Research & Therapy 12, no. 1 (2021): 317.

[326] S. H. Abd-Allah, S. M. Shalaby, H. F. Pasha, et al., “Mechanistic Action of Mesenchymal Stem Cell Injection in the Treatment of Chemically Induced Ovarian Failure in Rabbits,” Cytotherapy 15, no. 1 (2013): 64–75.

[327] H. Ø. Olesen, S. E. Pors, C. S. Adrados, et al., “Effects of Needle Puncturing on Re-vascularization and Follicle Survival in Xenotransplanted human Ovarian Tissue,” Reproductive Biology and Endocrinology [Electronic Resource]: RB&E 21, no. 1 (2023): 28.

[328] J. Cheng, X. Ruan, Y. Li, et al., “Effects of Hypoxia-preconditioned HucMSCs on Neovascularization and Follicle Survival in Frozen/Thawed human Ovarian Cortex Transplanted to Immunodeficient Mice,” Stem Cell Research & Therapy 13, no. 1 (2022): 474.

[329] S. G. Kristensen, H. Ø. Olesen, M. C. Zeuthen, S. E. Pors, C. Y. Andersen, and L. S. Mamsen, “Revascularization of human Ovarian Grafts Is Equally Efficient From both Sides of the Cortex Tissue,” Reproductive Biomedicine Online 44, no. 6 (2022): 991–994.

[330] M. M. Laronda, A. L. Rutz, S. Xiao, et al., “A Bioprosthetic Ovary Created Using 3D Printed Microporous Scaffolds Restores Ovarian Function in Sterilized Mice,” Nature Communications 8 (2017): 15261.

[331] A. Hassanpour, T. Talaei-Khozani, E. Kargar-Abarghouei, V. Razban, and Z. Vojdani, “Decellularized human Ovarian Scaffold Based on a Sodium Lauryl Ester Sulfate (SLES)-treated Protocol, as a Natural Three-dimensional Scaffold for Construction of Bioengineered Ovaries,” Stem Cell Research & Therapy 9, no. 1 (2018): 252.

[332] S. Ahmadian, S. Sheshpari, M. Pazhang, et al., “Intra-ovarian Injection of Platelet-rich Plasma Into Ovarian Tissue Promoted Rejuvenation in the Rat Model of Premature Ovarian Insufficiency and Restored Ovulation Rate via Angiogenesis Modulation,” Reproductive Biology and Endocrinology [Electronic Resource]: RB&E 18, no. 1 (2020): 78.

[333] T. T. A. Nguyen and I. Demeestere, “A Journey to Reach the Ovary Using Next-Generation Technologies,” International Journal of Molecular Sciences 24, no. 23 (2023): 16593.

[334] S. Yang, Y. Sun, W. Luo, et al., “Dominant Follicle-targeted Nanocarriers for GH Delivery to Alleviate Premature Ovarian Insufficiency,” Materials Today Bio 33 (2025): 101930.

[335] Y. Liu, H. Mu, Y. Chen, et al., “Follicular Fluid-derived Exosomes Rejuvenate Ovarian Aging Through miR-320a-3p-mediated FOXQ1 Inhibition,” Life Medicine 3, no. 1 (2024): lnae013.

[336] M. Lakshmanan, M. Saini, and M. Nune, “Exploring the Innovative Application of Cerium Oxide Nanoparticles for Addressing Oxidative Stress in Ovarian Tissue Regeneration,” Journal of Ovarian Research 17, no. 1 (2024): 241.

[337] B. N. Jahromi, S. Sadeghi, S. Alipour, M. E. Parsanezhad, and S. M. Alamdarloo, “Effect of Melatonin on the Outcome of Assisted Reproductive Technique Cycles in Women With Diminished Ovarian Reserve: A Double-Blinded Randomized Clinical Trial,” Iranian Journal of Medical Sciences 42, no. 1 (2017): 73–78.

[338] Y. Xu, V. Nisenblat, C. Lu, et al., “Pretreatment With Coenzyme Q10 Improves Ovarian Response and Embryo Quality in Low-prognosis Young Women With Decreased Ovarian Reserve: A Randomized Controlled Trial,” Reproductive Biology and Endocrinology [Electronic Resource]: RB&E 16, no. 1 (2018): 29.

[339] X. Li, Z. Wang, H. Wang, H. Xu, Y. Sheng, and F. Lian, “Role of N-acetylcysteine Treatment in Women With Advanced Age Undergoing IVF/ICSI Cycles: A Prospective Study,” Frontiers in Medicine (Lausanne) 9 (2022): 917146.

[340] S. Tinjić, D. Abazović, D. Ljubić, et al., “Influence of Autologous in Vitro Activation of Ovaries by Stem Cells and Growth Factors on Endocrine and Reproductive Function of Patients With Ovarian Insufficiency-A Clinical Trial Study,” International Journal of Fertility & Sterility 15, no. 3 (2021): 178–188.

[341] P. Igboeli, A. El Andaloussi, U. Sheikh, et al., “Intraovarian Injection of Autologous human Mesenchymal Stem Cells Increases Estrogen Production and Reduces Menopausal Symptoms in Women With Premature Ovarian Failure: Two Case Reports and a Review of the Literature,” Journal of Medical Case Reports 14, no. 1 (2020): 108.

[342] L. Weng, L. Wei, Q. Zhang, et al., “Safety and Efficacy of Allogenic human Amniotic Epithelial Cells Transplantation via Ovarian Artery in Patients With Premature Ovarian Failure: A Single-arm, Phase 1 Clinical Trial,” eClinicalMedicine 74 (2024): 102744.

[343] C. Navarro, P. T. Cabrera, and A. Teppa Garrán, “Comparative Analysis of the Use of Autologous Exosomes and Platelet-derived Growth Factors in Women With Premature Ovarian Insufficiency and Infertility: A Prospective, Randomized, Observational, Analytical Study,” Regenerative Therapy 30 (2025): 309–320.

[344] X. Chen, J. Zhang, N. Yin, et al., “Resveratrol in Disease Prevention and Health Promotion: A Role of the Gut Microbiome,” Critical Reviews in Food Science and Nutrition 64, no. 17 (2024): 5878–5895.

[345] M. Wu, L. Ma, L. Xue, et al., “Resveratrol Alleviates Chemotherapy-induced Oogonial Stem Cell Apoptosis and Ovarian Aging in Mice,” Aging (Albany NY) 11, no. 3 (2019): 1030–1044.

[346] K. Sevgin and P. Erguven, “SIRT1 overexpression by Melatonin and Resveratrol Combined Treatment Attenuates Premature Ovarian Failure Through Activation of SIRT1/FOXO3a/BCL2 Pathway,” Biochemical and Biophysical Research Communications 696 (2024): 149506.

[347] Y. Liang, M. L. Xu, X. Gao, et al., “Resveratrol Improves Ovarian state by Inhibiting Apoptosis of Granulosa Cells,” Gynecological Endocrinology 39, no. 1 (2023): 2181652.

[348] A. M. Posadino, R. Giordo, A. Cossu, et al., “Flavin Oxidase-Induced ROS Generation Modulates PKC Biphasic Effect of Resveratrol on Endothelial Cell Survival,” Biomolecules 9, no. 6 (2019): 209.

[349] F. Ragonese, L. Monarca, A. De Luca, et al., “Resveratrol Depolarizes the Membrane Potential in human Granulosa Cells and Promotes Mitochondrial Biogenesis,” Fertility and Sterility 115, no. 4 (2021): 1063–1073.

[350] A. Ochiai and K. Kuroda, “Preconception Resveratrol Intake Against Infertility: Friend or Foe?,” Reproductive Medicine and Biology 19, no. 2 (2020): 107–113.

[351] M. Abdellatif, S. Sedej, and G. Kroemer, “NAD(+) Metabolism in Cardiac Health, Aging, and Disease,” Circulation 144, no. 22 (2021): 1795–1817.

[352] M. S. Bonkowski and D. A. Sinclair, “Slowing Ageing by Design: The Rise of NAD(+) and Sirtuin-activating Compounds,” Nature Reviews Molecular Cell Biology 17, no. 11 (2016): 679–690.

[353] W. J. Ho, M. B. Marinova, D. R. Listijono, et al., “Fertility Protection During Chemotherapy Treatment by Boosting the NAD(P)(+) Metabolome,” EMBO Molecular Medicine 16, no. 10 (2024): 2583–2618.

[354] Q. Yang, L. Cong, Y. Wang, et al., “Increasing Ovarian NAD(+) Levels Improve Mitochondrial Functions and Reverse Ovarian Aging,” Free Radical Biology and Medicine 156 (2020): 1–10.

[355] H. Tamura, Y. Nakamura, A. Korkmaz, et al., “Melatonin and the Ovary: Physiological and Pathophysiological Implications,” Fertility and Sterility 92, no. 1 (2009): 328–343.

[356] L. M. Melhuish Beaupre, G. M. Brown, V. F. Gonçalves, and J. L. Kennedy, “Melatonin's Neuroprotective Role in Mitochondria and Its Potential as a Biomarker in Aging, Cognition and Psychiatric Disorders,” Translational Psychiatry 11, no. 1 (2021): 339.

[357] J. Zhang, Q. Chen, D. Du, et al., “Can Ovarian Aging be Delayed by Pharmacological Strategies?,” Aging (Albany NY) 11, no. 2 (2019): 817–832.

[358] C. Song, W. Peng, S. Yin, et al., “Melatonin Improves Age-induced Fertility Decline and Attenuates Ovarian Mitochondrial Oxidative Stress in Mice,” Scientific Reports 6 (2016): 35165.

[359] R. S. Barberino, T. Lins, A. P. O. Monte, et al., “Melatonin Attenuates Cyclophosphamide-Induced Primordial Follicle Loss by Interaction With MT(1) Receptor and Modulation of PTEN/Akt/FOXO3a Proteins in the Mouse Ovary,” Reproductive Sciences 29, no. 9 (2022): 2505–2514.

[360] H. Zhang, C. Li, D. Wen, et al., “Melatonin Improves the Quality of Maternally Aged Oocytes by Maintaining Intercellular Communication and Antioxidant Metabolite Supply,” Redox Biology 49 (2022): 102215.

[361] Y. Wang, S. Liu, F. Gan, D. Xiong, X. Zhang, and Z. Zheng, “Melatonin Levels and Embryo Quality in IVF Patients With Diminished Ovarian Reserve: A Comparative Study,” Reproductive Biology and Endocrinology [Electronic Resource]: RB&E 22, no. 1 (2024): 127.

[362] K. H. Tsui, C. J. Li, and L. T. Lin, “Melatonin Supplementation Attenuates Cuproptosis and Ferroptosis in Aging Cumulus and Granulosa Cells: Potential for Improving IVF Outcomes in Advanced Maternal Age,” Reproductive Biology and Endocrinology [Electronic Resource]: RB&E 22, no. 1 (2024): 138.

[363] H. Tamura, M. Jozaki, M. Tanabe, et al., “Importance of Melatonin in Assisted Reproductive Technology and Ovarian Aging,” International Journal of Molecular Sciences 21, no. 3 (2020): 1135.

[364] D. R. Meldrum, R. F. Casper, A. Diez-Juan, C. Simon, A. D. Domar, and R. Frydman, “Aging and the Environment Affect Gamete and Embryo Potential: Can We Intervene?,” Fertility and Sterility 105, no. 3 (2016): 548–559.

[365] C. H. Lee, M. K. Kang, D. H. Sohn, H. M. Kim, J. Yang, and S. J. Han, “Coenzyme Q10 Ameliorates the Quality of Mouse Oocytes During in Vitro Culture,” Zygote (Cambridge, England) 30, no. 2 (2022): 249–257.

[366] A. Ben-Meir, S. Yahalomi, B. Moshe, Y. Shufaro, B. Reubinoff, and A. Saada, “Coenzyme Q-dependent Mitochondrial respiratory Chain Activity in Granulosa Cells Is Reduced With Aging,” Fertility and Sterility 104, no. 3 (2015): 724–727.

[367] Y. Bentov, T. Hannam, A. Jurisicova, N. Esfandiari, and R. F. Casper, “Coenzyme Q10 Supplementation and Oocyte Aneuploidy in Women Undergoing IVF-ICSI Treatment,” Clinical Medicine Insights: Reproductive Health 8 (2014): 31–36.

[368] Y. Shang, N. Song, R. He, and M. Wu, “Antioxidants and Fertility in Women With Ovarian Aging: A Systematic Review and Meta-Analysis,” Advances in Nutrition 15, no. 8 (2024): 100273.

[369] V. Mokhtari, P. Afsharian, M. Shahhoseini, S. M. Kalantar, and A. Moini, “A Review on Various Uses of N-Acetyl Cysteine,” Cell Journal 19, no. 1 (2017): 11–17.

[370] G. F. Rushworth and I. L. Megson, “Existing and Potential Therapeutic Uses for N-acetylcysteine: The Need for Conversion to Intracellular Glutathione for Antioxidant Benefits,” Pharmacology & Therapeutics 141, no. 2 (2014): 150–159.

[371] L. G. Barrozo, L. Paulino, B. R. Silva, et al., “N-acetyl-cysteine and the Control of Oxidative Stress During in Vitro Ovarian Follicle Growth, Oocyte Maturation, Embryo Development and Cryopreservation,” Animal Reproduction Science 231 (2021): 106801.

[372] S. Zhang, Q. Liu, M. Chang, et al., “Chemotherapy Impairs Ovarian Function Through Excessive ROS-induced Ferroptosis,” Cell Death & Disease 14, no. 5 (2023): 340.

[373] M. Foretz, B. Guigas, L. Bertrand, M. Pollak, and B. Viollet, “Metformin: From Mechanisms of Action to Therapies,” Cell Metabolism 20, no. 6 (2014): 953–966.

[374] M. N. Pollak, “Investigating metformin for Cancer Prevention and Treatment: The End of the Beginning,” Cancer Discovery 2, no. 9 (2012): 778–790.

[375] B. Viollet, B. Guigas, N. Sanz Garcia, J. Leclerc, M. Foretz, and F. Andreelli, “Cellular and Molecular Mechanisms of Metformin: An Overview,” Clinical Science (London, England: 1979) 122, no. 6 (2012): 253–270.

[376] Y. Yang, X. Lu, N. Liu, et al., “Metformin Decelerates Aging Clock in Male Monkeys,” Cell 187, no. 22 (2024): 6358–6378.e29.

[377] J. M. Navarro-Pando, P. Bullón, M. D. Cordero, and E. Alcocer-Gómez, “Is AMP-Activated Protein Kinase Associated to the Metabolic Changes in Primary Ovarian Insufficiency?,” Antioxid Redox Signaling 33, no. 15 (2020): 1115–1121.

[378] M. Jinno, K. Kondou, and K. Teruya, “Low-dose Metformin Improves Pregnancy Rate in in Vitro Fertilization Repeaters Without Polycystic Ovary Syndrome: Prediction of Effectiveness by Multiple Parameters Related to Insulin Resistance,” Hormones (Athens) 9, no. 2 (2010): 161–170.

[379] J. Flory and K. Lipska, “Metformin in 2019,” Jama 321, no. 19 (2019): 1926–1927.

[380] Z. Liao, C. Liu, L. Wang, C. Sui, and H. Zhang, “Therapeutic Role of Mesenchymal Stem Cell-Derived Extracellular Vesicles in Female Reproductive Diseases,” Frontiers in Endocrinology (Lausanne) 12 (2021): 665645.

[381] S. Herraiz, M. Romeu, A. Buigues, et al., “Autologous Stem Cell Ovarian Transplantation to Increase Reproductive Potential in Patients Who Are Poor Responders,” Fertility and Sterility 110, no. 3 (2018): 496–505.e1.

[382] S. Zafardoust, S. Kazemnejad, M. Darzi, et al., “Intraovarian Administration of Autologous Menstrual Blood Derived-Mesenchymal Stromal Cells in Women With Premature Ovarian Failure,” Archives of Medical Research 54, no. 2 (2023): 135–144.

[383] S. Zafardoust, H. Didar, M. G. Ganagard, et al., “Intra-ovarian Injection of Autologous Menstrual Blood-derived-mesenchymal Stromal Cells: A Safe and Promising Method to Improve Pregnancy Rate in Poor Ovarian Responders,” Stem Cell Research & Therapy 16, no. 1 (2025): 171.

[384] M. Mashayekhi, E. Mirzadeh, Z. Chekini, et al., “Evaluation of Safety, Feasibility and Efficacy of Intra-ovarian Transplantation of Autologous Adipose Derived Mesenchymal Stromal Cells in Idiopathic Premature Ovarian Failure Patients: Non-randomized Clinical Trial, Phase I, First in human,” Journal of Ovarian Research 14, no. 1 (2021): 5.

[385] M. I. Cassim, T. Mohamed, J. K. Adam, C. Niesler, and A. Chikandiwa, “Use of Autologous Adipose-derived Mesenchymal Stem Cells for Ovarian Rejuvenation in Poor Responder IVF Patients: A Phase 1 Randomized Placebo-controlled Double-blind Crossover Study,” Global Reproductive Health 8, no. 2 (2023): e68.

[386] A. A. Diaz, H. Kubo, N. Handa, M. Hanna, and M. M. Laronda, “A Systematic Review of Ovarian Tissue Transplantation Outcomes by Ovarian Tissue Processing Size for Cryopreservation,” Frontiers in Endocrinology (Lausanne) 13 (2022): 918899.

[387] P. Thuwanut, E. C. R. Leonel, T. F. Rocha Ruiz, P. Sirayapiwat, S. G. Kristensen, and C. A. Amorim, “Human Ovarian Tissue Xenotransplantation: Advancements, Challenges, and Future Perspectives,” Human Reproduction 40, no. 3 (2025): 410–419.

[388] A. Najafi, E. Asadi, and J. D. Benson, “Ovarian Tissue Cryopreservation and Transplantation: A Review on Reactive Oxygen Species Generation and Antioxidant Therapy,” Cell and Tissue Research 393, no. 3 (2023): 401–423.

[389] M. M. Dolmans, T. Falcone, and P. Patrizio, “Importance of Patient Selection to Analyze in Vitro Fertilization Outcome With Transplanted Cryopreserved Ovarian Tissue,” Fertility and Sterility 114, no. 2 (2020): 279–280.

[390] H. Khattak, R. Malhas, L. Craciunas, et al., “Fresh and Cryopreserved Ovarian Tissue Transplantation for Preserving Reproductive and Endocrine Function: A Systematic Review and Individual Patient Data Meta-analysis,” Human Reproduction Update 28, no. 3 (2022): 400–416.

[391] R. Fabbri, R. Vicenti, V. Magnani, et al., “Ovarian Tissue Cryopreservation and Transplantation: 20 Years Experience in Bologna University,” Frontiers in Endocrinology (Lausanne) 13 (2022): 1035109.

[392] S. Lee, S. Ozkavukcu, and S. Y. Ku, “Current and Future Perspectives for Improving Ovarian Tissue Cryopreservation and Transplantation Outcomes for Cancer Patients,” Reproductive Sciences 28, no. 6 (2021): 1746–1758.

[393] M. M. Dolmans, V. Luyckx, J. Donnez, C. Y. Andersen, and T. Greve, “Risk of Transferring Malignant Cells With Transplanted Frozen-thawed Ovarian Tissue,” Fertility and Sterility 99, no. 6 (2013): 1514–1522.

[394] G. Pennarossa, M. Ghiringhelli, F. Gandolfi, and T. A. L. Brevini, “Whole-ovary Decellularization Generates an Effective 3D Bioscaffold for Ovarian Bioengineering,” Journal of Assisted Reproduction and Genetics 37, no. 6 (2020): 1329–1339.

[395] H. Jafari, A. Dadashzadeh, S. Moghassemi, P. Zahedi, C. A. Amorim, and A. Shavandi, “Ovarian Cell Encapsulation in an Enzymatically Crosslinked Silk-Based Hydrogel With Tunable Mechanical Properties,” Gels 7, no. 3 (2021): 138.

[396] A. B. Alshaikh, A. M. Padma, M. Dehlin, et al., “Decellularization and Recellularization of the Ovary for Bioengineering Applications; Studies in the Mouse,” Reproductive Biology and Endocrinology [Electronic Resource]: RB&E 18, no. 1 (2020): 75.

[397] L. K. McGinnis, L. J. Luense, and L. K. Christenson, “MicroRNA in Ovarian Biology and Disease,” Cold Spring Harbor Perspectives in Medicine 5, no. 9 (2015): a022962.

[398] M. Fraidakis, G. Giannakakis, A. Anifantaki, et al., “Intraovarian Platelet-Rich Plasma Injections: Safety and Thoughts on Efficacy Based on a Single Centre Experience with 469 Women,” Cureus 15, no. 5 (2023): e38674.

[399] M. Bakacak, M. S. Bostanci, F. İnanc, et al., “Protective Effect of Platelet Rich Plasma on Experimental Ischemia/Reperfusion Injury in Rat Ovary,” Gynecologic and Obstetric Investigation 81, no. 3 (2016): 225–231.

[400] M. Éliás, M. Kónya, Z. Kekk, et al., “Platelet-rich Plasma (PRP) Treatment of the Ovaries Significantly Improves Fertility Parameters and Reproductive Outcomes in Diminished Ovarian Reserve Patients: A Systematic Review and Meta-analysis,” Journal of Ovarian Research 17, no. 1 (2024): 104.

[401] Z. Wang, “Assessing Tumorigenicity in Stem Cell-Derived Therapeutic Products: A Critical Step in Safeguarding Regenerative Medicine,” Bioengineering (Basel) 10, no. 7 (2023): 857.

[402] E. Lezmi and N. Benvenisty, “The Tumorigenic Potential of Human Pluripotent Stem Cells,” Stem Cells Translational Medicine 11, no. 8 (2022): 791–796.

[403] H. Chen and Q. Li, “Recent Advances in Scalable Exosome Production: Challenges and Innovations,” Chinese Journal of Plastic and Reconstructive Surgery 7, no. 3 (2025): 149–163.

[404] Y. Wang, J. Xiong, K. Ouyang, et al., “Extracellular Vesicles: From Large-scale Production and Engineering to Clinical Applications,” Journal of Tissue Engineering 16 (2025): 20417314251319474.

[405] S. S. Palakurthi, B. Shah, S. Kapre, et al., “A Comprehensive Review of Challenges and Advances in Exosome-based Drug Delivery Systems,” Nanoscale Advances 6, no. 23 (2024): 5803–5826.

[406] E. A. Margolis, N. E. Friend, M. W. Rolle, E. Alsberg, and A. J. Putnam, “Manufacturing the Multiscale Vascular Hierarchy: Progress Toward Solving the Grand Challenge of Tissue Engineering,” Trends in Biotechnology 41, no. 11 (2023): 1400–1416.

[407] T. Mladenovska, P. F. Choong, G. G. Wallace, and C. D. O'Connell, “The Regulatory Challenge of 3D Bioprinting,” Regenerative Medicine 18, no. 8 (2023): 659–674.

[408] K. Joyce, Z. Buljovcic, G. Rosic, M. Kaszkin-Bettag, and A. Pandit, “Issues With Tissues: Trends in Tissue-Engineered Products in Clinical Trials in the European Union,” Tissue Engineering Part B: Reviews 29, no. 1 (2023): 78–88.

[409] Y. Li, J. Wang, Z. Zhang, et al., “Resveratrol Compares With Melatonin in Improving in Vitro Porcine Oocyte Maturation Under Heat Stress,” Journal of Animal Science and Biotechnology 7 (2016): 33.

RIGHTS & PERMISSIONS

2025 The Author(s). MedComm published by Sichuan International Medical Exchange & Promotion Association (SCIMEA) and John Wiley & Sons Australia, Ltd.